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Understanding, and adequately articulating how and what the patient feels and experiences 
during the progression of a disease and during drug treatment is an important aspect in a 
patient’s life. Yet this articulation does not always get appropriate attention and thus the 
patient experience may not be fully understood by others. Nor is it fully explored in drug 
development programs due to the lack of focus on patient outcomes. Drug development has 
in the past primarily focused on meeting the regulatory approval of the new drug. To gain 
regulatory approval a company has to provide evidence of the drug’s safety, and efficacy, 
combined with a favourable benefit-risk ratio. The patient benefits or patient concerns, 
especially in the case of cancer, is thus often masked within the clinical endpoints, such as 
overall survival or progression free survival, or if patient outcomes are measured, they may 
not be appropriately articulated in dialog between stakeholders, or in publications. 
 
Recent years have seen an upswing in pharmaceutical companies introducing a so-called 
patient-centric research and focus is shifting towards patient relevant endpoints. However, 
pharmaceutical companies do not always fully understand how such patient-centric research 
is to be conducted, and if data is collected, how to interpret the data and how to present the 
data to stakeholders. The two most important pharmaceutical drug regulators and approval 
bodies, at least in terms of millions of lives they potentially affect, the European Medicines 
Agency (EMA) and the Food and Drug Administration (FDA) have both in the recent years 
embraced the concept of patient-centricity, and patient experience in their guidance to the 
industry. There is an increased acceptance of this type of evidence in regulatory submissions, 
thus, opening opportunities for pharma companies to promote research towards patient 
relevant endpoints and evidence. 
 
It is with this background that this thesis is written and compiled, with the aim of discussing 
how Patient Reported Outcomes (PRO) research can, and should be integrated into 
pharmaceutical drug development, and how such results can be presented, while keeping in 
mind the many different stakeholders that need this information, ranging from regulatory 
agencies, to payers, physicians and patients. The thesis makes use of eight recent patient-
centred papers published in the field of prostate cancer.  
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The papers and the research make a number of important contributions by providing 
examples of different approaches on how the PRO analyses are conducted, exploring 
different way of reporting results and by linking the results of PRO evidence to clinical 
outcomes. Through the iterative learning process, which came as a result of the research I 
conducted over time and by exploring different analyses methods, ways of presenting results 
and presenting results to different journals, I learnt how to conduct this type of research, all 
the way from conceptualization, through data collection, analyses and reporting of results. 
Thus, by combining this learning, which was gained from this research, with the papers 
selected for this thesis, this has provided me with the structure and learning and legacy that I 
can bring forward from this research. It provides the basis for the construct of the framework 
presented in this thesis for how such Outcomes Research can be implemented in drug 
development. This blueprint and framework can be adapted to any disease area and can 
enhance the impact of the research, enhance new drug treatments, and help patient’s get the 
best and most suited treatment options. 
As an overall mantra of clinical drug development, we must embrace that the ultimate raison 
d’etre of any medicine or intervention, must be to the benefit of the patients and to improve 
their health.  
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Chapter 1:   Introduction 
 
1.1 Prostate cancer challenge 
Prostate cancer (PCa) is one of the most common cancers in men both in Europe (Ferlay et 
al., 2013) and worldwide (IACR, 2012). Moreover, in 2012, PCa represented the third most 
common cause of death from cancer in men in Europe (9.5% of the total) (Ferlay et al., 2013) 
and the fifth leading cause of death from cancer in men globally (6.6% of the total) (IACR, 
2012). Furthermore, PCa and metastatic PCa represent a significant burden to individuals, 
families and caregivers as well as healthcare systems in terms of costs (Alemayehu, 2010; Le, 
2013; Luengo-Fernandez et al., 2013) and healthcare resource utilisation (Dass, 2012). 
 
Patients with metastatic PCa have a poor prognosis (Bracarda et al., 2011, Heidenreich et al., 
2013, Kälin, 2011) and historically, the median survival was <2 years (Cookson et al, 2013). In 
the majority of patients with PCa, a number of disease- and treatment-related symptoms 
adversely affect Health-Related Quality of Life (HRQoL) (Payne, 2012, Holmstrom et al., 2018) 
which deteriorates as the disease progresses (Merseburger et al., 2013; Sullivan et al., 2007). 
Skeletal metastases represent a substantial burden, occurring in >90% of CRPC patients 
(Gater et al., 2011), and degenerate QoL, functionality and longevity in patients with mCRPC 
(Autio et al., 2012). 
 
While new prostate cancer treatments have been made available in recent years, greatly 
improving the life of PCa patients and prolonging their life expectancy, the extra choice of 
treatments also makes it harder for the treating physician, the payers and the patient to 
judge and understand which treatment option provides the best benefit-risk balance and is 
the most cost-effective. This is where Patient Reported Outcomes (PRO) data, if available and 
articulated in a comprehensive way can make a difference by providing patient relevant 
information to help decision making on benefits and risks. 
 
Prostate cancer and the disease progression constitute many different patient segments 
ranging from early disease, non-metastatic prostate cancer, patients still not treated with any 
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drug and still hormone sensitive, to the most advanced stage of chemo-therapy resistant, 
metastatic prostate cancer patients (mCRPC). For clarity of the thesis, these various patients’ 
segments are not specified in the thesis, as the different segments are irrelevant to the 
scientific question and hypothesis at hand. Hence, the reference to Prostate Cancer, 
regardless of disease segment or sub-group, will simply be given as PCa throughout this 
thesis, except for a few instances where it makes sense to specify this. 
 
1.2 Aims of the Thesis 
 
The aim of the thesis is to demonstrate and discuss how the use of PRO data in 
pharmaceutical drug development can enhance the understanding of prostate cancer during 
the disease progression.  
 
The PRO data will help differentiate between treatment options and articulate patient 
relevant impact of treatments, both positive and negative impacts and outcomes, thus 
reducing uncertainty in decision making for stakeholders. The stakeholders, representing the 
target audience for the PRO papers will include regulators, such as the FDA and EMA, Health 
Technology Assessment Bodies (HTABs), payers, physicians, caregivers and of course the 
patient. The papers used in the thesis as examples of PRO related research communication 
will provide added clarity of the benefits of the drug to the stakeholders, and thus facilitate 
their decision making on how to effectively use the drug, and help drugs gain faster approval, 
faster reimbursement and as a result reach patients faster, which help improve patients’ 
lives. Thus, the audience for all of these papers have been the stakeholders in patient care 
decision making, ranging from the patient, the physicians, HTABs, regulators and payers. 
 
With my position as an Outcomes Researcher within the pharmaceutical industry, the natural 
focus, and many times the only means to conduct Outcomes Research is by using PROs in our 
clinical trials. A more holistic view on the Patient Experience, including the caregiver and 
other outcomes such as patient preferences, is sometimes possible to include in pharma 
research, although this requires a bigger logistical effort to get acceptance within companies 
and thus more challenging to implement. The exception perhaps being qualitative patient 
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interviews. As mentioned earlier, the industry, including my own company is now waking up 
to the concept of Patient Centricity, which means the trend is for the wider concepts of 
Patient Experience, Patient Preferences, Caregiver Experience and other Patient Outcomes, 
gaining in understanding and thus acceptance and can be more broadly built into the clinical 
trials in the future. However, in the context of this thesis and what has been technically 
possible to integrate in my research is first of all and foremost PRO based research. 
Despite the constraints of focusing on PROs and PRO outcomes, I have been able to 
implement PROs in all clinical studies and also actively managed an evolution of our clinical 
research on how the PROs are implemented, analysed and reported on in our prostate cancer 
studies. This evolution will become evident through the papers I have chosen to build the 
thesis on. 
 
The thesis will use eight papers, where the present author was the key instigator and sole 
health outcomes member of the primary research team (clinical team), and a co-author in all 
papers. The clinical teams are multi-disciplinary teams with representatives from medical, 
regulatory, toxicology, statistics, and other departments, each represented by, mostly, a 
single person, or subject matter expert. As I was the subject matter expert, and only 
Outcomes Researcher in the clinical team, the implication of this was that I was the person 
who conceptually planned, integrated the plans and ensured the analyses were undertaken 
and reported from the Outcomes Research conducted in the trials.  
 
This responsibility called for clear conceptual planning of the research. This included the 
endpoint and PRO instrument selection, securing the implementation of this in the clinical 
studies, followed by the compilation of the statistical analyses plan (SAP), which most of the 
time was written as a separate PRO focused SAP, different from the primary SAP which 
reported on the key clinical finding. This was followed by ensuring the data was collected, 
then conducting the PRO analyses as per the SAP and finally reporting the results. Once the 
results are understood, publication were planned together with the larger clinical and 
medical team. Most often, the primary clinical paper reported on only a small part of the PRO 
results. Therefore, the aim for me was always to secure additional papers were published, 
where the focus was on the detailed PRO results. These publications, by nature of this 
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process will only be focused upon, after the primary paper, which reported on the primary 
endpoints.  
 
Through this research, which spanned some six to seven years, it was possible to evolve and 
learn from one study to another. This was particularly true when it came to how the analyses 
plans, the SAP of the PRO data were constructed and executed. The papers thus provide both 
the substance and examples for how PRO can be analysed and reported on, as well as 
address some further aims and objectives of the thesis, such as: 
• How can pharmaceutical development integrate PRO research more effectively? 
• How are conceptual models for patient signs, symptoms and impacts built? 
• How do we prospectively define HRQoL analyses in pharmaceutical research? 
• How can HRQoL data most effectively be presented, using different analyses 
models? 
• Can we link clinical relevance of high impact safety complications and the 
association between HRQoL and clinical outcomes? 
 
As a conclusion of my work and the thesis: 
The use of PROs in pharmaceutical drug development enhances the understanding of 
disease progression and provides means to improve the outcome of patient’s care, by 
articulating patient relevant impacts, and through this data reduce uncertainty in decision 
making and thus facilitate and expedite access of new treatments to patients. 
 
With this background, the purpose of this thesis is to advance the understanding of PRO data, 
enhance the common knowledge of how to analyse the evidence and how such research can 
be integrated into pharmaceutical development in prostate cancer. The thesis will provide 
examples and guidance as to how PRO research can be implemented in drug development, 
showcase the value of conducting different types of analyses of the PRO and HRQoL data and 
how this can all be tied into more patient focused information, as well as clinical outcome 
relevant end points. It is a complex area and simple messages and solutions are not easily 
available, hence the needs of the different stakeholders will require different type of analyses 
and different type of evidence made available to them. All of my eight papers I selected to 
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support my thesis will together build a framework for how PRO research can be conducted to 
cater for these stakeholders. 
 
1.3 Patient in the focus of pharmaceutical research – Patient centricity  
 
The role of the patient and patient reported data, and the concept of patient centricity is one 
of the key focus areas and buzzwords in today’s pharmaceutical industry and in drug 
development. The pharmaceutical industry, in collaboration with the regulatory agencies such 
as the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) are 
taking steps to provide guidance and improve ways medicines are developed as well as the 
methodologies used to analyse the data collected from the patients through the patient 
reported outcomes information. With these measures, the patient, as a key player in the 
treatment paradigm, is brought forward, and information directly relevant to the patient is 
developed and presented in a way better understood by the patient, as well as decision makers. 
 
Due to an ever-increasing cost of health care and drug cost, in oncology in particular, while at 
the same time there are limited healthcare resources and increasing doubts of the benefit and 
cost-effectiveness of many new drugs, estimating the economic and humanistic burden of 
treatment is extremely important. In particular, by providing information and evidence of the 
drug benefit, and the patient benefit of the treatments, and by providing it in understandable 
formats will decrease uncertainty and help decision making by stakeholders. This is critical for 
all stakeholders, such as healthcare policy makers, health systems, physicians, patients, 
employers, and society overall. It is in this context that the patient reported outcome 
information plays an important role. As part of the multi-factorial decision-making the role of 
PRO derived information can help articulate differences in treatment options and thus, the 
request for such information and use of it has increased significantly in the last years (Basch, 
2018; Gnanasakthy and DeMuro, 2015; Shields, 2016) 
 
Any data derived directly from the patients is defined as Clinical Outcomes Assessments (COAs) 
or Patient Reported Outcomes (PROs). The concept of a COA is the broader of the two and is 
defined by the FDA (Food and Drug Administration) (FDA, 2009) as: 
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Clinical outcome assessment — A COA is any assessment that may be influenced by human 
choices, judgment, or motivation and may support either direct or indirect evidence of 
treatment benefit. Unlike biomarkers that rely completely on an automated process or 
algorithm, COAs depend on the implementation, interpretation, and reporting from a patient, 
a clinician, or an observer. The four types of COAs are patient-reported outcome (PRO) 
measures, clinician-reported outcome (ClinRO) measures, observer-reported outcome 
(ObsRO) measures, and performance outcome (PerfO) measures. (Walton et al., 2015) 
The Patient Reported Outcomes - Patient-reported outcomes (PRO) is an umbrella term that 
includes outcomes data reported directly by the patient. It is one source of data that may be 
used to describe a patient’s condition and response to treatment. It includes such outcomes 
as global impressions, functional status, well-being, symptoms, health related quality of life 
(HRQL), satisfaction with treatment, and treatment adherence (Walton et al., 2015). 
  
The two concepts of PRO and COA, and their relationship to each other are illustrated in the 
Figure below (Figure 1). In the context of this thesis, the more relevant of the two is the PRO, 
as it is a direct measure of the Health-Related Quality of Life (HRQoL), or the Quality of Life 
(QoL) as reported by the patient. By definition, and strictly speaking, the QoL and HRQoL are 
not exactly the same thing but are frequently used interchangeably. In health care, the 
HRQoL is an assessment of how the individual’s well-being may be affected over time by a 
disease, disability or disorder. Throughout the thesis, the use of “PRO instrument”, 
instruments", “PRO questionnaire” and “PROs” are to be read as synonyms. The meaning and 
intent of these are the same. 
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Figure 1.1 Patient outcome assessments types (COA) (from Acquadro et al, 2003, page 524) 
 
1.4 Patient reported outcome instruments in prostate cancer 
 
Of all disease areas, perhaps cancer has one the one most profound effect on the patient and 
thus is extremely relevant when it comes to how a disease and treatment affects the patient’s 
Quality of Life. To have the diagnosis of cancer will already significantly affect the patient, given 
the common knowledge and understanding of the gravity of the diagnosis (Flynn, 2013). Any 
subsequent, additional burden to the patient should be avoided.  
 
In addition, at the end-of-life stage one must also ensure any negative treatment effect is out-
weighted by a significantly improved life expectancy and/or improvement, or stabilisation of 
the quality of life. Life expectancy of cancer patients has fortunately been increasing over the 
years with the introduction of new treatment modalities. The increase in life expectancy will 
vary from disease to disease, but in advanced prostate cancer today, a minimum of 3 months 
increase in overall survival is expected, should a new treatment be regarded as providing 
additional benefit to existing drugs. New drugs also need to out-weigh any negative treatment 
effects or side effects. Some cancers, such as gastric cancer may be in a more fortunate 
situation and patients can expect several months (6-12 months) increase in survival. Others, 
such as breast cancer or blood cancers have now access to treatments that can increase life 
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expectancy with several years, or even cure the disease (Flynn, 2013). The implications are thus 
for prostate cancer, given an increase in cost of these treatments, that patients should truly 
benefit from the new treatments while society can expect to be using limited healthcare 
resources wisely. This further strengthen the need for patient relevant information to enable 
educated decision-making. 
 
To measure and assess QoL in PCa is best done by combining two types of PRO instruments. 
First with a Non-disease specific instruments, and secondly with a Disease specific 
instruments. The non-disease specific or generic instruments can be used for any disease and 
will use general questions to measure QoL. The disease specific ones will include signs and 
symptoms bother that is specific to one disease. These two types of instruments will provide 
both a comparative assessment of how the disease impacts the patient, as compared to other 
diseases, while the disease specific questions will drill down on specific symptoms that are 
relevant, in this case in prostate cancer.  
Examples of the Non-specific instruments are: 
• European Quality of Life 5-Domain (EQ-5D) questionnaire 
• Functional Assessment of Cancer Therapy–General (FACT-G) questionnaire 
• European Organization for Research and Treatment of Cancer (EORTC) Quality of Life 
Questionnaire (EORTC QLQC30),  
Examples of Disease specific instruments are: 
• Functional Assessment of Cancer Therapy–Prostate (FACT-P) 
• European Organization for Research and Treatment of Cancer (EORTC) QLQ-PR25, 
prostate cancer questionnaire. 
The studies done with enzalutamide in prostate cancer have made use of these instruments as 
well as measured pain, through a pain instrument called Brief Pain Instrument (BI).  
 
1.5 Integrating PROs and payer relevant endpoints in pharmaceutical development 
 
The clinical research in pharmaceutical drug development is done in defined phases called 
phase 0, phase 1, phase 2, phase 3 and phase 4. The phase 0, phase 1, phase 2 and phase 3 are 
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designed to collect evidence on the drug safety, efficacy and tolerability and will complete the 
regulatory submission made available to regulatory authorities across the globe. The phase 0 
– 2 is where dose, dose regiments, primary efficacy measures, effect size and endpoints are 
explored and confirmed. If no safety concerns are found in the phase 1 or phase 2 studies, the 
research moves into phase 3, usually consisting of at least two large, multi-center, randomized 
and double-blind studies (RCT’s). These RCT’s are designed to provide all necessary clinical 
efficacy evidence for obtaining the regulatory approval. Important point to note is that the 
RCT’s focus on clinical efficacy, not cost-effectiveness. The RCT’s will include thousands of 
patients, except for rare or orphan disease indications where the total number of patients may 
be smaller. Endpoints and measures used in the phase 3 studies should all be confirmed and 
validated and thus provide solid scientific evidence of the safety and efficacy and include 
sufficient data on the patient relevant outcome, including PRO derived information. Once the 
regulatory submission is done and regulatory approval has been obtained, the companies 
continues to conduct clinical studies, and these are referred to as phase 4 studies. 
 
The pharmaceutical companies have for many years, and to some extent still today focused the 
phase 1 to phase 3 research mainly on obtaining the regulatory approval, in other words not 
fully considered the needs of Health Technology Assessment Bodies (HTABs), other payers and 
patients. The regulatory data package, especially when conducted as placebo-controlled 
studies, has always been less relevant and less informative for the HTABs, payers and patients. 
The placebo-controlled studies pose a specific problem because comparative data with other 
treatments options is missing. Payers and patients need to understand what different 
treatment options provide and how they differ from each other. In placebo-controlled studies 
this reference point and comparative aspect is not covered and hence provides only out-of-
context information.   The regulatory submission to the US Food and Drug Administration (FDA) 
and the European Union (EU) European Medicines Agency (EMA), will clear the first hurdle, but 
has not always been met with approval, or facilitated the reimbursement submissions. About 
20% of Health Technology Assessments (HTA) made by UK National Institute for Health and 
Care Excellence (NICE) are not recommending the drugs for use, although EMA has already 
granted regulatory approval for these drugs (NICE, 2018). 
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Research reported in 2013 found that despite the call for inclusion of more patient centric 
research the studies including PROs remained relatively low (between 30-35% of studies) and 
the trend in the years dating back to early 2000 and up to 2011 remained the same (Brim and 
Pearson, 2013). While analysing the [European Organization for Research and Treatment of 
Cancer] (EORTC) and their RCT’s it has been shown that the inclusion of PRO and HRQoL 
instruments has however increased over the period of 2002-2013, and this has contributed to 
altering clinical practice and support and help obtain regulatory approvals for oncology trials 
(Zikos, 2014) . In a more recent paper from 2017, it was noted that in drug approvals between 
2009-2013, still, unfortunately a majority of drugs entered the market without evidence of 
benefit on survival or QoL (Davis et al., 2017). 
 
The importance of the PRO data as a relevant and informative part of the decision-making has 
many recent examples. In December 2017, the Chairman of the German Federal Joint 
Committee (G-BA) noted that the G-BA like to see QoL more strongly considered in the 
assessment process. The G-BA noted that one-fifth of the eighty-eight oncology medicines that 
have undergone a benefit assessment procedure are judged not to show an added benefit and 
suggest oncology drugs should in fact be negatively assessed if their submission do not include 
information on Quality of Life. (GB-A, 2017)  
 
Recent thinking includes building up an endpoint strategy, including a PRO and patient centric 
strategy. The most important question to ask when building up an endpoint strategy and for 
focusing the data points in studies will be; what does one want to say about our drug? An 
endpoint model such as the one below can help facilitate dialog with stakeholders, and to link, 
and integrate PRO building blocks into the research program of new drug development (Sheilds, 
2013).  
 
Table 1.1: Adapted End-Point model for clinical development program, a hypothetical model. 
The model outline how primary and secondary claims will be defined as endpoints, and how 
they can be measured. 
Claim Concept End point Assessment type 
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Primary endpoints    
Treatment reduces tumour 
size 
Tumour size or 
death 
Progression free survival is 
defined as time from 




Date of death 
Secondary endpoints    
Treatment improves 
disease related symptoms 
by X points compared with 
other treatment 
Pain Proportion of patients with 
>50% reduction in pain score 
from baseline to week 18 
PRO instrument  
Source: Shields et al., 2016 (page 191) 
 
Endpoint models, such as the one described above can greatly help in designing and conducting 
research that is better designed and adapted to other stakeholder needs, including the HTABs, 
payers and the patients. 
 
In this thesis, I build a framework for how to conduct HRQoL and PRO research in prostate 
cancer, by building on my papers in this field. The basis is to include PROs in clinical research, 
reach out to the patients for qualitative patient interviews, analyse the PRO data in multiple 
ways and finally bridge the patient reported outcomes and benefits to clinical endpoints. 
Eventually this can enhance how prostate cancer research is conducted and greatly benefit the 
patients as well as save health care resources. 
 
1.6 Overview of publications and contribution of these to the thesis 
 
At the time when this Outcomes Research on enzalutamide in prostate cancer started, there 
had been no new treatment modalities, no new medical treatments introduced for prostate 
cancer for many years. Thus, limited opportunities had existed in terms of advancing the field 
of Outcomes Research in prostate cancer. The field was therefore mature for input and 
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knowledge sharing, partly by providing educational material on how to conduct Outcomes 
Research in this space, such as I have reported in papers 1 and 2, and partly through 
reporting on the effect of the new treatment of enzalutamide in the various stages of 
prostate cancer, as I have done with papers 3, 4, 5 and 6. Furthermore, these earlier papers 
provided the opportunity to further explore the link of HRQoL outcomes and clinical 
endpoints, as well as providing patient relevant information on the effect of the drug through 
item analyses, as done in papers 7 and 8. 
 
All of the papers included in the thesis have, therefore, been included with a clear rationale. 
Together they build up a story of how enzalutamide works in prostate cancer, as well as 
providing a framework for how PRO integration in drug development can be conducted in 
order to provide more meaningful and understandable information to the patient, physician 
and other stakeholders, and thus increase the impact of the results. As mentioned earlier, the 
focus in the research, and in this thesis is on PRO results as the only available proxy for the 
wider concept of patient experience. Ideally, other patient experience measures, caregiver 
experiences or wider patient-centric outcomes, including for instance societal aspects or 
patient preferences, should be included in such research. However, the pre-requisite for a 
successful implantation of such a broad Outcomes Research focus is to work with a well-
established clinical team with previous experience with such work, and thus work with a 
team with an advanced understanding of the benefits of Outcomes Research and not having 
to extensively educate the team of the meaning of each work. It also requires access to 
sufficient funds and resources, both when it comes to economic and humanistic support. 
 
Another, quite unique aspect that enabled this research to be conducted in the whole 
complexity as reported in these papers, was the ability to follow one compound and one line 
of research for a longer time-period. Outcomes Researchers in the drug industry are very 
seldom able to follow a full life-cycle for one compound, meaning that one may be included 
in a few studies, perhaps in the development of one indication, but rarely in many studies 
and covering a whole range of indications. The fact that I was able to follow enzalutamide 
from the very early clinical studies and first disease stage, to the later disease stage studies, 
several years down the line, provided me with a unique opportunity to conduct this research, 
building on results and experience, one after the other, and learn from previous mistakes. 
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The framework, which is part of the conclusion of my thesis, is thus building on the 
experience gained from this opportunity and all the Outcomes Research I conducted 
throughout the years.  
 
When the research and the first papers were initiated and conducted, the clinical team had 
very limited understanding of how Outcomes Research should be conducted, or even why 
this type of research needed to be done, given that regulatory submissions did not require 
such data. In general, pharma companies still today struggle to meet these needs, especially 
in small start-up companies where a global mind-set and understanding of HTABs, or other 
stakeholders’ needs is not well established and thus these endpoints are often omitted. In 
Chapter 3, Paper 1 addresses these shortcomings and guides industry researchers on how to 
plan, integrate and conduct HTAB relevant evidence generation research.  
 
As an Outcomes Researcher I deemed it necessary to have a high-level and focused guidance 
in order to guide the internal discussion on Outcomes Research and in general on Health 
Economics and Outcomes Research (HEOR) in the public domain. This paper therefore 
created a foundation for what the HEOR team should focus on, and why. Without this basic 
understanding, the clinical teams would have continued to struggle to understand the need 
for this research. 
 
Paper 2 in Chapter 3 reports on the construct of the so-called conceptual model based on 
qualitative research from patient interviews. This is the first step one should take in any 
disease area, not well documented in publications. The clinical team that I was working with 
at the time had no direct experience or previous exposure of this type of research. In 
addition, only limited resource and budget was provided for my Outcomes Research plans. As 
a consequence, I struggled to conduct state-of-the-art research, such as outlined in the ISPOR 
guidance (Patrick et al., 2011a; 2011b). The paper reflects these shortcomings. At a later 
stage, one of our subsequent research papers, albeit a different disease segment, 
(Holmstrom et al., 2018) would become a better reference for such research. The later paper 
is evidence for how my evolution in the conduct of Outcomes Research and qualitative 
research has progressed. 
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Qualitative patient interview research will consist of two steps. The first one is the conduct of 
a full systematic literature review, or alternatively a targeted literature review, to ensure one 
has a full comprehension of what has already been published and discussed in the terms of 
patient reported symptoms and impacts of the disease. The second phase is to conduct 
interviews with, both clinicians specialised in the treatment of the disease and secondly, and 
with patients with the disease. This is included in Chapter 3 discussing the integration of PROs 
in PCa research. 
 
Moving on to Chapter 4, Paper 3 reports on the analyses and results of the QoL results from 
the prostate cancer clinical phase 3 study of PREVAIL (PCa). The paper reports on our results 
from the second large phase 3 study, with focus on the PRO and HRQoL data. This paper 
represents the first effort to separate the PRO and HRQoL results from the so-called primary 
paper whilst publishing a scientifically interesting paper focusing on patient outcomes, rather 
than clinical endpoints. The paper covers all of the HRQoL results, while also graphically 
representing the results as a time-to-event and change from baseline graph. The analyses 
performed was focusing on the instrument specific scoring algorithms. This classic approach 
for reporting the PRO results, focus on the composite scores resulting from the pre-defined 
scoring guidance. This will always be instrument specific. The FACT-P instrument will report 
so-called “Total Score”, which is a composite score summarised from 39 different items. 
While these are very informative in providing trend analyses and a graphical illustration of the 
impact of the disease progression under different treatment arms, it is not always easy to 
understand what these results mean for the patient.  
 
Paper 4 in Chapter 4 reports on the QoL results in the prostate cancer phase 3 AFFIRM PCa 
study using a different methodology. At this stage of my research I had access to two of our 
larger phase 3 studies (AFFIRM and PREVAIL), and the data quantity started to build up. I 
discussed extensively with the clinical team how we could best analyse the PRO and HRQoL 
data, and equally, how I could best represent the data in a meaningful way to cover the 
interests of different stakeholders and different readers. The results from the studies 
indicated a clear benefit of enzalutamide over placebo, while no harmful effect was 
identified. However, scientifically we must understand what drives the positive results from 
enzalutamide, while also ensuring the signal was real. In this study I included testing on 
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missing values, sensitivity analyses and different way to graphically present the results. The 
Mixed Effects model for Repeated Measure (MMRM) as well as a Pattern Mixture Model 
(PMM) were applied as a secondary analysis to address missing values issues. The paper also 
explores the way results are presented using not only longitudinal change from baseline 
graphs, but also using a Cumulative Distribution Function (CDF) to enable an easy overview of 
the two populations (treated versus placebo) and the population response. 
 
The last part of Chapter 4, Papers 5 & 6 provide new information not reported before. Firstly, 
by providing comparative information relevant to other treatment options and secondly by 
highlighting the clinical aspects of key disease related symptoms, that of Skeletal Related 
Events (SREs). The SREs are mostly due to metastasis in the bone, or bone fractures. These 
studies were only achieved through my extensive and persistent dialog with the clinical team 
on how we can best dialog with stakeholders on relative effectiveness terms. For HTABs and 
payers, there are two important aspects when making decisions on the use of enzalutamide, 
or any new drug, should the drug be used, and is the benefit, risk and cost justified? Firstly, 
questions related to how enzalutamide compares to other active treatments of PCa (Paper 5). 
Secondly related to cost and possible economic cost-savings or other benefits the drug may 
provide (Paper 6). For both of these aspects the papers use the Outcomes Research 
endpoints, to highlight the benefit of enzalutamide. The comparative data is also very 
important and relevant for the treating physician and for the patient, enabling the patient to 
be part of a decision on how to pursue treatment of the prostate cancer. Both papers 
providing comparative data on both benefits as well as safety concerns. These two papers 
complement the Chapter 4 on Analyses of the PRO instruments. 
 
The common themes and foci in all previous papers was to explore various ways of analysing 
the PRO data, analysing the impact of missing data, as well as graphically presenting the data 
in different ways. Based on the analyses, I was able to say that overall QoL scores were 
positive and showed a benefit of enzalutamide over placebo. However, questions that 
remained unanswered was, what was driving this positive effect for the patient and can we 




As a next step, I therefore took a deeper dive into the different domain and item analyses of 
the PRO results. The opportunity that had opened up for this type of research, was in part 
driven by new guidance received from the FDA (FDA, 2017). However, in addition to this, the 
other key question was to show how HRQoL and PRO results could help the clinician 
understand and relate to the PRO data by linking PRO results with clinical outcomes. 
Therefore, the last two papers (Papers 7 & 8) in Chapter 5 report on different ways of 
analysing the PRO data as well as investigating the association between HRQoL and overall 
survival (OS) and radiographic progression free survival (rPFS). Paper 7 is an example of what 
I believe is the current trend in the field of PRO and HRQoL research today. The current trend 
is to make use of all items in a PRO instrument, not just composite summary scores, while 
analysing them as individual items and looking at impacts that are relevant for the patient 
while, expressing the results in such a way that is more intuitive for the patient and physician 
to understand. Paper 8 also brings in the physician relevant information into the overall 
picture of PRO research by making associations between endpoints used by the physician, 
such as the OS outcome associated with PRO outcomes. If PROs can be used as a prognostic 
factor of outcomes this will be of great value to clinicians. Work has been done on using QoL 
as prognostic of baseline value, but few on over-time values of QoL measures.  
 
While discussing with clinicians the meaning of PRO and HRQoL data, in my experience, there 
is often a lack of understanding of what the data mean for them as clinicians and how to 
interpret the data. While they all agree that measuring QoL as part of the treatment benefits 
is important, the PRO data fails, as currently reported, to make it relevant for the treating 
physician. Thus, by creating the link between clinical outcomes and the outcomes from PROs, 
this will greatly enhance the acceptance of PRO data among clinicians and in particular if the 
HRQoL data can be used as prognostic factors. 
 
1.7 Chapter summary 
This chapter has given an overview of the landscape of PROs, what PROs are, how they are 
used in prostate cancer. In addition, it discusses how PROs are used for serving the needs of 
both regulators and payers and how they help define an endpoint model for drug development, 
which in turn guides the overall clinical study design. It introduced the challenges the industry 
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has been facing with the integration of PROs in drug development and how the regulatory 
environment is currently changing and embracing more patient centricity in their assessments 
of new drugs. 
With my publications in PCa, and through the gradual increased understanding of both the 
compound, enzalutamide, as well as how to best analyse the PRO data, the papers re-create 
the story-line as to, what PROs to include, how to analyse the data and how to represent the 
data through graphical and other means for stakeholders to understand. At the same time, 
there was an increased awareness within my company for how to conduct Outcomes Research; 
which facilitated possibilities to conduct the PCa related research and get acceptance for 
publishing the work, in its own right.  
 
It is also important to understand the regulated environment the pharma industry has to live 
within while conducting clinical research. To improve the patient centred research and improve 
PCa outcomes using PRO data need to consider these constraints. 
 
The next chapter will be discussion the Epidemiology and Burden of the Disease of Prostate 
Cancer. As one of the four most common cancers in the world, it takes an important position 
in the overall burden on health care resources and in terms of patients impacted. 
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Chapter 2:   Epidemiology and Burden of Disease 
 
The chapter 1 laid the foundation of understanding the importance of prostate cancer and 
the need for advancing the treatment of prostate cancer in order to reduce number deaths 
and improve patients’ lives and their QoL. The chapter has also given an overview of the 
world of PROs and how these fits with pharmaceutical drug development, helping companies 
to become more patient centric. This chapter will provide an overview of prostate cancer, the 
disease burden and epidemiology of the disease. 
2.1 Overview 
 
It is estimated that 8.2 million people died from cancer worldwide in 2012. The most common 
cancers are lung, bowel, breast and prostate cancers. Together they accounted for almost half 
(48%) of all cancer deaths in the UK in 2014 (Flynn, 2013). The physical and psychosocial effects 
of Prostate cancer are profound for patients and their families and spouses (Flynn, 2013). This 
includes skeletal related events (spinal cord compression, bone metastases), lower urinary 
tract symptoms, fatigue, pain and a few other related events. In the majority of patients with 
Prostate cancer, a number of disease- and treatment-related symptoms adversely affect 
HRQoL, which is diminished compared with the general population, and QoL deteriorates as 
the disease progresses (Merseburger, 2013). 
 
In a population-based cost analysis, the economic costs of all cancers to the European Union 
(EU) was €126 billion in 2009; the cost associated with Prostate cancer was the fourth highest 
at €8.43 billion (7% of overall cancer costs) (Luengo-Fernandez et al., 2013). Cost estimates 
included care in the primary, outpatient, emergency, and inpatient settings, drugs, unpaid care 
from relatives/friends, and lost earnings.  
 
The treatment landscape of prostate cancer changed dramatically a few years ago when new 
androgen signalling agents such as enzalutamide and abiraterone entered the market. Except 
for bicalutamide and androgen deprivation treatments, the options for advanced prostate 
cancer has long been chemotherapy. Chemotherapy has a high burden on the patient in 
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general and avoiding chemotherapy or delaying such treatment will in general be a desirable 
outcome. The distribution of patient age and incidence of prostate cancer as shown in Figure 
2.1 corresponds well with the population included in the clinical studies AFFIRM and PREVAIL. 
 
 
Figure 2.1: PCa 2011-2013 average number of new cases per year and age-specific incidence 
rates per 100,000 population, males, UK (UKCR, 2014).  
 
2.2 Prostate cancer and hormone resistant prostate cancer 
 
Androgen deprivation therapy (ADT) is first-line treatment for advanced/metastatic Prostate 
cancer. In recent years, luteinising hormone releasing- hormone (LHRH) agonists have been 
the most commonly used form of ADT in advanced Prostate cancer. More than 80% of 
patients show a positive response to androgen ablation (Heinlein and Chang, 2004). However, 
despite this good initial response, disease progresses despite continuous hormonal 
manipulation after around 2–3 years (Amaral et al., 2012; Karantanos et al, 2013). The 
median age of men with prostate cancer is in the 70s (Toren and Gleave, 2013) and skeletal 
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metastases occur in >90% of prostate cancer patients (Gater et al., 2011). In contrast, based 
on US data from the Surveillance, Epidemiology, and End Results (SEER) database, only ~4% 
of all newly diagnosed patients present with metastatic Prostate cancer (NCI, 2014; Toren 
and Gleave, 2013; NCRAS, 2012).  
 
In the past, various terms have been used to describe Prostate cancer that relapses after 
initial ADT; these include androgen-independent Prostate cancer, hormone-refractory 
Prostate cancer, and hormone-independent Prostate cancer. In recent years, these terms 
have been superseded by the term ‘castrate-resistant Prostate cancer’ (CRPC). 
 
Metastatic castrate-resistant prostate cancer is the terminal stage of PCa, and patients at this 
stage with prostate cancer have a poor prognosis (Bracarda et al., 2011; Heidenreich et al., 
2013; Kälin, 2011). Metastatic PCa median survival for men has been less than 2 years 
(Cookson et al., 2013). As the disease progresses, quality of life (QoL) deteriorates. 
 
As stated earlier, and for the purpose of this thesis, there is no distinction between the 
different stages of prostate cancer when analysing the PRO results. All are reported 
throughout the thesis under the umbrella of PCa. 
 
2.3 Epidemiology 
Epidemiologic trends in Prostate cancer may reflect changes in age and Prostate cancer stage 
at diagnosis over recent decades. Specifically, men are being diagnosed at younger ages, and 
in the USA for example, the rate of stage IV disease has increased among the younger 
population (Cetin et al., 2010). Worldwide, Prostate cancer is the second most common 
cancer in men and the fifth leading cause of death from cancer in men. Within Europe, 
Prostate cancer incidence rates are highest in Northern and Western European countries and 
the lowest in Central and Eastern European countries (IACR, 2012). In the USA, incidence and 
mortality is higher in African American men compared with other racial/ethnic groups (NCI, 
2014). It is not clear why this is, but it is believed that diet, genes and hormones all play a part 
in this (McIntosh, 1997) 
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Worldwide data indicate that Prostate cancer is the fourth most common cancer in both 
sexes combined and the second most common in men (IACR, 2012). Thus, in 2012, an 
estimated 1.1 million men were diagnosed with Prostate cancer globally, representing 15% of 
all cancers diagnosed in men; almost 70% of cases occurred in more developed regions.  
 
 
Figure 2.2: Worldwide incidence of prostate cancer mortality 2012. 
Estimated age-standardised rates (World) per 100,000 (IACR, 2012) 
 
2.4 Patient burden 
Health outcomes were assessed using the EQ-5D in 3,477 Prostate cancer patients (of whom 
1405 [40%] had prostate cancer and 1,119 had prostate cancer) in a large analysis across EU-5 
countries (2009–2010) (Sternberg et al., 2013). Using EQ-5D VAS scores, HRQoL were poorer 
in metastatic and prostate cancer patients: averages (out of a possible 100) were 74.8, 71.6, 
66.3 and 66.5 for patients with localised, locally advanced, metastatic and prostate cancer, 
respectively. 
 
The physical and psychosocial effects of prostate cancer are profound for patients and their 
partners and family (Flynn, 2013). QoL in advanced Prostate cancer has been well 
documented but studies involving patients with prostate cancer, where appropriate QoL data 
is collected, has been sparse. In the majority of patients with prostate cancer, a number of 
disease- and treatment related- symptoms adversely affect health-related quality of life 
 28 
(HRQoL) (Payne, 2012), which is diminished compared with the general population, and QoL 
deteriorates as the disease progresses (Merseburger et al., 2013; Sullivan et al., 2007). 
QoL outcomes in PCa in Germany were assessed in a 1-year observational, cross-sectional, 
prospective study in 37 specialised Prostate cancer centres. Interim results from 101 patients 
showed that the mean EQ-5D visual analogue scale (VAS) score (out of a possible 100) was 
47.8. Mean overall EQ-5D single index utility score (which ranges from 0 to 1, where 1 = full 
health) was 0.72:  0.81, 0.66 and 0.64 for pre-chemotherapy, post-chemotherapy and 
ongoing chemotherapy patients, respectively. In addition, 67.3% of patients had pain or 
discomfort, 58.1% problems to perform usual activities, 53.1% mobility problems, 37.7% 
anxiety/depression troubles and 32.7% self-care problems (Wolff, 2012). QoL was also 
assessed using the FACT-P tool. The total score (out of a possible 156) was 101.5 and mean 
subscale scores were; physical well-being, 19.5; social/family well-being, 20.6; emotional 
well-being, 17.0; functional well-being, 15.7; Prostate cancer subscale, 28.6 (Wolff, 2012). 
In a recent UK study in 163 men with prostate cancer, HRQoL data were collected via an 
online survey and included EQ-5D and EORTC QLQ-C30, supplemented by a 25-item EORTC-
8D Prostate cancer–specific questionnaire module (Lloyd et al., 2015). This study stratified 
patients by disease state. Utility values elicited by the EQ-5D ranged from 0.830 for the 
asymptomatic/mildly symptomatic pre-chemotherapy disease state to 0.625 for the 
symptomatic pre-chemotherapy disease state (maximum possible score = 1, full health). EQ-
5D VAS values ranged from 77.5 to 56.2, respectively (out of a possible 100). For all of these 
instruments, utility values/VAS scores for patients receiving chemotherapy or post 
chemotherapy- were within the ranges reported for the pre-chemotherapy groups. 
 
EQ-5D health status in PCa appears to be lower than the general population norm (Sullivan et 
al., 2007; Wu, 2007). This was confirmed in two US observational studies using the EQ-5D 
single index utility score which showed the mean baseline EQ-5D score for patients with 
prostate cancer to be 0.603 in one study (Sullivan et al., 2007), and 0.64 in a second (Wu, 
2007). Both well below the US population norm of 0.87 (Luo et al., 2005), while a score of 
1.00 signified best imaginable health. The second study also showed that prostate cancer 
patients scored lower than population norms on the generic measure, FACT-G, with a total 
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score of 75.4 (higher score signifies better HRQoL) (Wu, 2007). The US population norm is at 
80.1 (Brucker et al., 2005). This confirms the impact PCa has on the patient’s well-being, with 
a progressively deterioration of the QoL of the patients as the disease progress. 
Prostate cancer patients also show impairment in most HRQoL domains using cancer-specific 
instruments. In a multinational, observational cohort study of oncology practices, 280 
prostate cancer patients from Australia, Canada, France, Germany, Italy, and the UK were 
assessed using the EORTC QLQ-C30 and FACT-P Prostate cancer Subscale (PCS) in addition to 
EQ-5D (Sullivan et al., 2007). As prostate cancer progresses, a decline in HRQoL was observed. 
Thus, a significant decline from baseline in FACT-P PCS, EQ-5D and 10 of the 14 EORTC 
domains was seen at 3, 6 and 9 months (Sullivan et al., 2007).  
 
Improved HRQoL has been linked to better clinical outcomes in prostate cancer. Analysis of 
data from a phase III trial of the endothelin receptor antagonist atrasentan in prostate cancer 
patients found that better baseline and 12-week change in HRQoL are strongly associated 
with better survival, time to disease progression and pain prognosis than those with worse 
HRQoL (Sullivan et al., 2007).  
 
2.5 Impact of skeletal-related events (SREs) on QoL 
Skeletal metastases occur in >90% of prostate cancer patients (Gater et al., 2011). Skeletal 
metastases often lead to reduced QoL, functionality and longevity in patients with prostate 
cancer (Autio et al., 2012). It has been shown that a higher number of bone lesions is 
associated with shorter progression-free survival (PFS) and overall survival (OS) in patients 
with prostate cancer (Tait et al., 2014), and a higher volume of bone metastasis is associated 
with reduced OS in prostate cancer (Perez-Lopez et al., 2016). Common complications of 
skeletal metastases include bone pain, vertebral collapse or deformity, pathological fractures, 
spinal cord compression (SCC) and osteoporosis (which may cause fractures). Because of their 
high frequency in prostate cancer, skeletal metastases are responsible for a considerable 
proportion of patient morbidity, primarily through complications known as SREs (Brown and 
Sim, 2010). SREs (defined as a pathological fracture, SCC, palliative radiation to bone, or 
surgery to bone (Weinfurt et al., 2005) lead to significant functional declines in patients’ daily 
lives. Patients with SREs experience clinically meaningful declines in physical and emotional 
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well-being after radiation to bone and pathologic fractures and declines in functional well-
being after radiation. SREs were found to impact patients’ QoL in metastatic Prostate cancer 
patients (DePuy et al., 2007); patients with SREs in the initial period had significantly worse 
HRQoL than those without SREs. 
 
2.6 Cost of illness and Economic Burden 
 
As the new treatments of prostate cancer and for cancer in general are approved, the 
associated cost of treatment is increasing. Therefore, estimating the economic burden of 
cancer is increasingly important for healthcare policy makers, health systems, physicians, 
employers, and society overall to enable decisions on treatment options to be evidence 
based. In a population-based cost analysis, the economic cost of all cancers to the EU was 
€126 billion in 2009; the cost associated with Prostate cancer was the fourth highest at €8.43 
billion (7% of overall cancer costs) (Luengo-Fernandez et al., 2013). Cost estimates included 
care in the primary, outpatient, emergency, and inpatient settings, drugs, unpaid care from 
relatives/friends, and lost earnings. European cost of illness data in prostate cancer are scarce 
and costs for prostate cancer patients can be difficult to discern due to the lack of a specific 
International Classification of Diseases code. However, the recent development and approval 
of new therapies that improve survival in prostate cancer will likely make the cost of disease 
management an even greater issue. Implications of this is that more data, such as PRO and 
QoL data is needed, in order to properly assess the new treatments. 
 
Prostate cancer management and prostate cancer in particular, can be complex, challenging, 
and costly (Lew, 2013). The cost of prostate cancer varies according to the speciality 
(urologist or oncologist) and type of physician providing the PCa care (Engel-Nitz et al., 2011). 
In a retrospective US claims analysis, first-year total adjusted healthcare costs ranged from 




2.6.1 Cost associated with SRE’s 
Patients with bone metastases (>1.5 million worldwide) frequently develop SREs which add a 
substantial cost to management for healthcare payers. A Belgian study estimated the 
cost-per SRE- (extrapolated to 2010 costs) in patients (2005–2007) with bone metastases 
secondary to solid tumours (breast, prostate and lung) (Body et al., 2013). The average 
cost-per SRE- for Prostate cancer, based on the weighted average of inpatient and outpatient 
costs, was €1,592 for radiation to bone, €3,938 for a vertebral fracture, and €5,125 for a non-
vertebral fracture. Costs per patients were €11,092 and €6,382 for surgery to bone and SCC, 
respectively. 
 
High hospital SRE-treatment costs were also revealed by a small retrospective Portuguese 
chart review (152 patients from nine hospitals) of costs associated with SRE treatment in 
breast (n = 121) and prostate (n = 31) cancer patients with bone metastases and ≥1 SRE 
during the preceding 12 months (Felix et al., 2011). Mean annual SRE treatment cost per 
patient was similar for breast (€5,963) and Prostate cancer (€5,711). Mean cost per single 
episode ranged from €1,485 (radiotherapy) to €13,203 (SCC). Early onset of bone metastasis 
and diagnosis of bone metastases at or after the occurrence of the first SRE were associated 
with higher SRE treatment costs. 
 
Figure 2.3: Mean treatment cost by Skeletal Related Events type for Portuguese patients with 
breast or Prostate cancer. (Felix et al., 2011) 
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2.7 Chapter summary 
 
The health status of prostate cancer patients appears to be lower than the general 
population norm and health outcomes are poorer in metastatic and prostate cancer patients 
compared with earlier disease stages. Furthermore, in prostate cancer over half of patients 
seem to experience pain or discomfort, or problems with mobility or in performing usual 
activities. While improved HRQoL has been linked to better clinical outcomes in prostate 
cancer, patients show impairment in most HRQoL domains and HRQoL declines as prostate 
cancer progresses. The economic burden of prostate cancer is considerable.  
 
The next chapter will discuss how PRO instruments are integrated in prostate cancer 
research. The focus is on getting the timing right, when to measure outcomes, how to 









As noted earlier, the conduct of pharmaceutical research is a conduct of research in a very 
controlled and regulated environment. There is a whole set of guidance as to how to conduct 
clinical research according to Good Clinical Practice (GCP) as well as agreed guidelines set out 
by the International Council for Harmonization (ICH). In addition, the hurdles for achieving 
regulatory approval and hence marketing authorization is set out by the regulators, mainly 
the FDA in US, the EMA in Europe and PMDA in Japan. Much of the clinical research design in 
the pre-approval phase (Phases 0-3) has been driven by these guidelines. This chapter will 
discuss this guidance, in relation to Patient Reported Outcome (PRO) research, and how this 
is evolving. 
 
3.2 Regulatory and HTA Bodies and framework for drug development and PRO 
research 
While there is plenty of detailed guidance for the drug development industry when it comes 
to the conduct of clinical trials through international guidelines and the regulatory agency 
guidance’s issued by the FDA or the EMA, there is much less so from the HTABs. This 
obviously has been one reason for the skewing of the focus towards the regulatory approval. 
 
The Committee for Medicinal Products for Human use (CHMP), which is part of the scientific 
committee of the European Medicines Agency (EMEA, who later changed the name to EMA) 
issued, a Reflection paper on the use of HRQL measures in the evaluation of medicinal 
products back in 2005 (EMA, 2005). This guidance came into effect as of January 2006. The 
EMEA guidance was a general guidance on aspects to consider when including PROs in clinical 
trials, and they stated clearly that they do not provide guidance on how PROs should 
methodologically be developed. They provided guidance on study design and statistical 
methods. Specifically, they had recommendations for how to deal with multiplicity and 
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stressed the importance of PROs in oncology trials. However, PROs were in general seen as 
“not mandatory” and concerning multiplicity, the use of a hierarchical testing, the PROs were 
seen as secondary endpoints. 
 
At the same time, the FDA issued a first Draft guidance for Industry on how to proceed with 
Patient Reported Outcome measures in order to support Medical product development and 
labelling claims. The FDA in 2009 issued the final guidance, the industry started to take note 
of how PROs could be integrated into drug development and what methodologies should be 
used for developing, and validating the PRO instruments (FDA, 2009). The FDA guidance was 
much more detailed (as opposed to the more general EMA guidance) and more guiding with 
regards to how to develop a new PRO instrument, starting with an Endpoint Model, a 
Conceptual Framework and ensuring both content validity and reliability and ability to detect 
change. The guidance also provided guidance as to considerations for clinical trial design, 
blinding and randomization, clinical trial quality control and how to handle missing data. 
Furthermore, it made guidance on statistical considerations and using multiple and 
composite endpoints. 
 
The HTABs have followed the regulatory guidance from the EMA, the FDA, and very few 
specific details or guidance has been given apart from providing section heading for inclusion 
of PRO and HRQoL relevant data in submissions. A more recent development, however, is a 
collaboration between regulators, namely the EMA and European HTABs. This collaboration 
has evolved significantly in recent years and facilitated a joint scientific review and advice 
structures set up by the European network for HTAs (EUnetHTA) and their Joint Action 3 
initiative (EUnetHTA, 2013). 
 
Many HTABs will encourage HRQoL data to be included in the application. The German 
Institute for Quality and efficiency in Health Care (IQWIG) in their Version 5.0 of 10 July 2017 
General Method’s document includes QoL as an assessment criterion to be used. However, 
concerning the methodologies, they refer to external guidance from the International Society 
of Quality of Life (ISOQOL) methods. The EUnetHTA guideline issued in February 2013 
(Health-related Quality of life and utility measures) does provide guidance on methodologies 
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related to use of HRQoL data as part of the endpoint strategy to support the assessment of 
relative effectiveness of pharmaceuticals (EUnetHTA, 2013).  
Furthermore, the FDA recently issued a new Guidance for Patient-Focused Drug Development 
under the 21st Century Cures Act, (FDA, 2017). This guidance is a significant milestone and 
very important as it puts the focus of drug development right at the patient. The guidance 
elevates the relevance and acceptance of HRQoL evidence. The EMA has also issued further 
guidance for qualification of novel methodologies (EMA, 2013; EMA, 2017). As a result of 
these changes, recent examples where PRO data has been used to support a regulatory label 
has been greatly enhanced (EMC, 2018). This means additional evidence and meaningful 
information is made available to stakeholders, while accepting analyses and methodologies 
previously discarded by the authorities.  
  
The methodology, or the way the PRO generated information is analysed is key in terms of 
how useful the information will be to stakeholders. Before 2006-2009, there was little 
published guidance in terms of standardisation of how the data should be analysed to meet 
regulators needs. That is not to say there was not a steady evolution of methodologies 
developed by academic institutions and researchers, but there was no general understanding 
of how methodologies should be applied to clinical studies and drug development. This lack 
of guidance improved drastically with the FDA & EMEA guidance in place (Bottomley et al., 
2009).  
 
It is with this background the first research paper was written, as a general guidance to the 
industry on how to conduct clinical research and integrate both the needs of the regulatory 
agencies as well as the HTABs and ultimately the patients, payers and physicians while 
providing scientific evidence to support the new drugs developed. 
 
3.3 Study Summary and Critique (Paper 1) 
Health economics and outcomes research within drug development. Challenges and 
opportunities for reimbursement and market access within biopharma research. (vanNooten 
F, Holmstrom S, Green J, Wiklund I, Odeyemi I, Wilcox T). Drug Discovery Today Vol 17, 11/12, 
June 2012) http://doi:10.1016/j.drudis.2012.01.021  
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The industry, and in particular the clinical team with whom I carried out my Outcomes 
Research has been struggling to fully comprehend and understand how to conduct patient, 
payer and HTABs relevant research. Therefore, there was a need to have a relevant 
publication to refer to, on how to conduct such research. I therefore wrote the paper to have 
a published reference and framework to help and guide the team on how to think about, and 
how to structure the relevant Outcomes and Economics research while conducting regulatory 
clinical studies. The pharmaceutical industry in general has been driven in their clinical 
research, primarily by meeting the needs of the regulatory agencies as fast, efficiently and 
effectively as possible. The regulatory, clinical and medical departments therefore drive the 
research with this in mind. Within these departments, there has thus not been a good 
understanding of what type of HRQoL and HTABs related research need to be conducted, 
how to include it, when to perform it, and outright why such research is needed.  
 
The paper built a framework for how to integrate HTABs and payer relevant data collection and 
data generation into the pharmaceutical development of phase 1-4. There are two dimensions 
and focus areas that are built into the suggested framework. The first one and the most 
important one is on the timing of the work. When do you need to start the work? What are the 
time points for the optimal collection of the data, and what clinical study phase is most suitable 
for this and for which type of research?  
 
One of the first insights from this research was on the timing of the necessary research should 
be collected, in other words when should data and evidence be generated and how is data 
collected? I therefore concluded that much of the work for HTABs and payer relevant output 
should start in early phase 2, or even earlier in the case where new PRO instruments need to 
be developed. The most relevant data should be available and ready for dissemination at the 
time of the regulatory submission. This way, relevant data will be used to support early HTA 
submissions and payer negotiations. 
 
The second element to consider is which type of research is to be conducted, and what type of 
data should be collected. We identified three main categories of such research.  
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1. Firstly, the Patient related research. This is research related to understanding the 
treatment and disease burden, the signs, symptoms and impacts of the disease on the 
patient. This insight will then guide the research into specific and adapted PRO 
instruments, which collect the relevant information in a structured and validated 
fashion. 
2. Secondly, the Disease related research. The focus here is for understanding of the 
disease, the treatment options, treatment guidance, the epidemiology, disease 
progression, socio-economic impact and cost consequences point of view. 
3. Third and last point is the Payer related research, including economical modelling. This 
includes understanding the payer environment, the cost drivers, the treatment benefits, 
the cost of treatment alternatives, cost savings and cost benefits from treatments, 
which all is built into the economical cost-effectiveness models and budget impact 
models. 
 
The Figure 3.1 below, extracted from the paper, illustrates the two dimensions of the 
pharmaceutical drug development and how to integrate HTA/payer related work, including the 
PRO focused work. 
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Figure 3.1 extracted from my paper on implementing HEOR in drug development, (van 
Nooten et al., 2012). The figure illustrates what type and when evidence gathering must be 
implement in order to ensure the evidence is generated in time for HTA submissions. 
 
The strength of the paper is the simplicity in which the topic is covered. It provides easy to 
understand and simple guidance to the main activities that must be covered and 
implemented, when conducting pharmaceutical drug development. There are still relatively 
few papers providing this type of guidance, which means newcomers in the industry are 
lacking appropriate guidance through peer-reviewed papers. 
 
Most importantly, the paper provided a helpful reference for my internal audience, in order 
to help the clinical team understand the basics of Outcomes Research and 
Pharmacoeconomics of drug research. The paper is still being cited as a general introduction 
paper for how to conduct HEOR research within the pharma industry, with 27 citations 
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(Google Scholar (2019) [Accessed on July 21st, 2019]) https://scholar.google.com/, and with 
over six hundred reads (Research Gate. (2019) Research Gate stats [Online] [Accessed on July 
21st, 2019]) http://www.researchgate.net/   
 
In terms of the limitations of the paper, one would be the opposite of the strength; that is, it 
does not provide specific details as to how to do the research as it focus more on the 
strategic elements, which are the Patient Related outcomes, Disease related research and 
Payer related outcomes. It is also difficult to provide very specific guidance without being 
specific to one disease area or one pharmaceutical compound as more detailed guidance will 
need to consider treatment specific guidance, general clinical practice and treatment 
algorithms used in the disease area.  
 
Another limitation is the fact that the focus is primarily on how to deal with implementation 
within an organization conducting drug development. The equally important part is the 
external environment and the engagement with HTABs for early dialog. Early Scientific Advice 
should be part of implementation strategy for new compounds. This point is highlighted in 
the general conclusion, in section 6.2.1 of my thesis, where I discuss how to build the 
framework for integration of PROs in pharmaceutical research. More recent papers have also 
called for a similar type of framework; and addressed internal challenges in implementing 
HTAB relevant research in pharmaceutical development (Oraiopoulos and Dunlop, 2017). 
 
While the first paper provides an overview of how to conduct the patient centric research, 
among other HEOR related research, the next paper provides more detailed guidance as to 
the first step for how to conduct patient interview research.  In this paper, the patient takes 
first stage and dialog is conducted directly with the patients. The benefit from doing this is 




3.4 Study Summary and Critique (Paper 2) 
Symptoms and Impact in Non-Metastatic Castration-Resistant Prostate cancer: Qualitative 
Study Findings. (Tomaszewski E, Moise P, Krupnik R, Downing J, Meyer M, Naidoo S, 
Holmstrom S). Patient, March 2017. 
DOI: 10.1007/s40271-017-0227-y  
 
The research question I was requested to reply to from within my clinical team when this 
research started, was what specific guidance I could provide in terms of PROs and patient 
relevant endpoints that should be included in future PCa studies, (given that we advance our 
studies in new disease stages). The priority question for me was to ensure I have conducted 
qualitative research with patient interviews. As noted in the first chapter, different 
constraints both in terms of resource availability and in terms of budgetary restrictions meant 
that the implementation of this research was hampered by these constraints. This qualitative 
research represents the first ever, that my company, and my clinical team had ever been 
exposed to. It was hence a substantial effort to get this research off the ground and approved 
as the concept was new for everybody. However, within the wider community of Outcomes 
Research such qualitative research is already well established and best-practice guidance is 
available from the ISPOR working group (Patrick et al. 2011a, b).  
As per guidance from the FDA and EMA, any evidence supporting patient centric research 
should start by understanding the complete patient experience, in other words the picture of 
the patient signs, symptoms and impacts of the disease. This paper summarises the 
qualitative study we performed to understand this in the field of prostate cancer. The 
objective of the study was to develop a conceptual framework for patients in non-metastatic 
castration-resistant prostate cancer. The conceptual framework is a structure where patient’s 
symptoms and impacts of the disease are mapped out (Patrick et al., 2011a, b).  
 
A literature review was conducted as a search of peer-reviewed literature in PubMed, as well 
as searching for patient blogs, patient foundations and organizations websites. A first 
categorization of the signs, symptoms and impacts was created based on these publications. 
The second step was to conduct semi-structured interviews of clinical experts managing and 
treating patients with prostate cancer. This included both oncologists as well as urologists. 
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The concepts identified in the first step literature review were also reviewed and discussed by 
the study team to confirm the appropriateness of these concepts. The third step, and perhaps 
the most important one for this type of research, was the conduct of the patient interviews. 
The interviews followed a semi-structured qualitative Patient Interview Guide, based on the 
literature and clinician interview input. Patients were asked both open-ended as well as 
probing questions focusing on symptoms and impacts of living with prostate cancer. 
Information on frequency, severity, duration and other precipitating factors of symptoms and 
impacts and how these disturbed their lives was collected. It is important to ensure that all 
salient symptoms and impacts are captured and thus a saturation table was prepared to 
ensure all relevant concepts were captured. Saturation is defined as the point where no new 
unique signs, symptoms or impacts are reported by the patients in the open-ended interview. 
From the 17 patients interviewed for this study we did unfortunately not reach an absolute 
saturation, as four new symptoms were still reported in the last interviews. However, as the 
most salient symptoms and impacts had reached saturation the decision that the conceptual 
model sufficiently reflected the patient experience in this prostate cancer population was 
taken.  
 
The study concluded that there were 35 distinct symptoms, which were categorised as 
urinary, sexual, hormonal, gastrointestinal and other. The symptoms that were most 
frequently mentioned, as well as had the highest interference rating were erectile 
dysfunction, loss of libido, urinary urgency, incontinence and hot flashes. In terms of the 
impacts, the most frequently mentioned were emotional, physical and socio-environmental.  
The conceptual model created based on the literature and the two interview steps 
summarises the key signs/symptoms of the disease as well as the immediate and distal 
impact on the patient.  
 
The Figure 3.2 below, which is extracted from my paper, illustrates the conceptual model. 
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Figure 3.2, from my paper on patient interview (Tomaszewski et al., 2017). This is the 
conceptual model on prostate cancer that the study documented on signs, symptoms and 
impacts of prostate cancer. 
 
This research helped in gaining a solid understanding of the how PCa patients feel and how 
they experience the disease impact; in this new, unknown disease stage. There have been 
relatively few papers reporting on qualitative research in this prostate cancer patient 
segment. Both for regulatory approval, and for HTAB negotiations, the paper provides a basis 
for patient relevant endpoints, linking the outcomes directly to how the patients QoL and 
how these outcomes can improve their life. Without this link to the patient, it is difficult to 
confirm that claims and outcomes are relevant to the patient himself and that they have any 
clinical relevance. This research, and other such patient concept elicitation studies, will also 
inform treatment guidelines, issued by medical associations, and help anchor them to the 
patient needs, hence making policies more relevant and adapted to clinical practice.  
There are some limitations with the study. One point for discussion is if the patient concept 
elicitation should be done before the physician interviews. One can argue both ways, as one 
informs the other. However, the patient concept elicitation is the most pertinent one, as it 
needs to adequately report on the patient experience, while the physician concept elicitation 
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will provide a better understanding of how the symptoms and impacts may relate to 
treatments rather than the disease. This may be a justification for conducting patient 
interviews first, which we did not do in this paper. 
 
Another point is the fact that patients selected were self-reported as non-metastatic prostate 
cancer patients. As the patients were selected from a database, access to internet may bias 
the population. Moreover, the diagnosis in the database is not confirmed by a physician and 
may be incorrect. The fact that full saturation on the concepts reported was not reached 
should be noted in future research and if need be modifying the construct of the conceptual 
model. 
 
As stated in chapter one, a later qualitative research paper (Holmstrom et al., 2018) was 
undertaken at a time where my company had grown in understanding for this line of 
research. This enabled me to obtain both appropriate funding for a more thorough research 
approach, as well as to obtain internal support, especially through discussions with our 
medical team, which further enhanced the study protocol. Nevertheless, paper 2 contributed 
at the time with new insights as we constructed the conceptual framework to illustrate the 
patient experience based on both the physical and emotional domains as well as other 
impacts such as self-care; many of these had not appropriately been considered when 
designing clinical studies so far. This paper was most likely to act as a tipping point for the 
company, for a deeper comprehension of the importance of engaging with the patient, and 
not only focusing on clinical efficacy and safety aspects. The Outcomes Research I needed to 
conduct to support enzalutamide would thereafter become easier to obtain approval for and 
be funded 
 
3.5 Chapter Summary 
To support the patient centric research in prostate cancer, two important activities need to 
take place. Firstly, the clinical studies and the design of the studies need to correspond with 
the evidence generation needs of the HTABs and the work must be done at an early stage of 
the clinical study program, usually in phase 2. Secondly, patient interviews need to be 
conducted early on to ensure a complete picture of the patient’s symptom burden and 
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impacts of the disease and the treatments is available. This will guide much of the patient 
centric research, the selection of the PROs and protocol design that ensures adequate data 
collection with meaningful data collection time points and duration that match the disease 
progression. All of the research needs to be guided by a strategic plan and consider all of the 
regulatory and HTAB guidelines. 
 
The next chapter will discuss the analyses of PRO data collected in the clinical studies. As 
instruments have pre-defined analyses algorithms and scoring manuals, all associated with 
documented validation work and validations documented to show validity of the instrument, 
most of the papers will follow these pre-defined guidelines. The reported papers report 
results from scoring guidance.  
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The previous chapter provided an outline as to how we create the foundation for 
understanding patient outcomes, and patient centric research. What type of research is 
needed and how do we ensure the evidence is collected in the early stages of clinical 
research? It discussed the importance of reaching out to patients in order to document the 
signs, the symptoms and the impact on the patient, as derived both from the disease and the 
treatments. When all of this is correctly executed, the next steps will be analysing the PRO & 
HRQoL data you have collected.  
Most PRO instrument provides pre-defined algorithms on how to calculate and report results 
and summary scores. This guidance is collated in so called Scoring Manuals. The instrument 
developer usually develops these at the time of the instrument development. The benefit of 
these Scoring Manuals is that results can be presented in a way that allows a comparison 
between studies, as they are performed in a standardised manner. This chapter will discuss 
how the PRO data from the studies were analysed and reported using these pre-defined 
guidance’s and algorithms. 
 
4.2 Study Summary and Critique (Paper 3) 
Effect of enzalutamide on health-related quality of life, pain and skeletal-related events in 
asymptomatic and minimally symptomatic, chemotherapy-naïve patients with metastatic 
castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial. 
(Loriot Y, Miller K, Sternberg C, Fizazi K, DeBono J, Chowdhury S, Higano C, Noonberg S, 
Holmstrom S, Mansbach H, Perabo F, Phung D, Ivanescu C, Skaltsa K, Beer T, Tombal B). 
Lancet Oncology Vol 16 May 2015. 




The publication is the first paper where the PRO analyses for enzalutamide, were separated 
out from the key clinical paper where primary endpoints had been reported. Thus, a separate 
SAP was constructed for the PRO analyses, with a focus on post-hoc analyses of all PRO 
instruments included in the study. At this stage of my research it was important to focus the 
Outcomes Research methodology on an approach that can easily be referenced and justified 
to the internal clinical team as a validated research method in order to gain acceptance. 
Therefore, the established scoring algorithms were implemented in our SAP at this point in 
time.  
 
The publication reports on the HRQoL results from the PCa clinical phase 3 study of PREVAIL. 
The objective of this paper was to examine the secondary endpoints, as defined in the study 
protocol. This included change from baseline, percentage improvement and time to 
deterioration in pain and HRQoL, as well as the proportion of patients with Skeletal-related 
events. 
 
The study prospectively collected three PROs, the Functional Assessment of Cancer Therapy-
Prostate (FACT-P), the EQ-5D and the Brief Pain Inventory (BPI) at several time points, 
including the baseline values at the start of the study. The improvement or deterioration of 
the patients HRQoL was measured through these instruments and using pre-defined 
thresholds. Most PRO instruments will have pre-defined thresholds to indicate which change 
in score is indicative of a clinically meaningful difference. This threshold is called the 
Minimally Important Difference (MID), or MCID (minimal clinically important difference). The 
MID is usually reported with a range and this range can be used to interpret either group 
differences for a population, or the individual patient. The lower end of the range is used to 
interpret the group difference, whereas the upper range should be used to interpret the 
individual patients change because the measurement errors will be larger for an individual 
patient and thus represent a larger variance. 
 
The time to first HRQoL deterioration was calculated as the time from the date of 
randomisation to the date of first recorded deterioration. Patients had to complete at least 
one question at an assessment point in order to fulfil questionnaire compliance. To get an 
idea on the longitudinal changes of HRQoL, the change from baseline was analysed using a 
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mixed-effects model for repeated measures, while controlling for baseline covariates. The 
Mixed-effects models for repeat measures use all data available and assumes that missing 
observations are at random. However, as it is also possible that missing values are not at 
random, additional sensitivity analyses were performed using a pattern-mixture model with 
placebo-based pattern imputation. Both models used data up to week 61. 
 
The results showed that no clinically meaningful decline was observed during the first 25 
weeks while on enzalutamide treatment, using the FACT-P total score and the prostate 
cancer subscale. The placebo arm however showed a higher than MID decline at all visits. The 
delay in decline in the HRQoL in the enzalutamide arm was confirmed with the sensitivity 
analyses. Also as measured through the EQ-5D utility index there was a beneficial effect, as 
well as with the Visual Analog Scale (VAS), as indicated through the change from baseline 
scores. Looking at the pain, as measured by the BPI, patients had less deterioration with 
enzalutamide at week 25 as compared to placebo. 
The Figure 3.2 below illustrates an extract from the paper on the results of the FACT-P total 
score and prostate cancer subscale adjusted mean change from baseline. 
 
Figure 3.2. Extract illustration from the paper reporting the results over time of FACT-P total 
scores (graph A), and the Prostate cancer subscale (graph B), with both treatment arms of 
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enzalutamide and placebo. The grey area of the graph indicates where the difference reaches 
a clinically meaningful change in the total score (Loriot et al., 2015). 
 
Overall, the paper concluded that there was a significant and clinically meaningful benefit 
from enzalutamide, as compared to placebo in maintaining HRQoL over time as well as in the 
time to the first skeletal related event (SRE). We believe this was the first report of EQ-5D 
responses and SRE assessments in this prostate cancer population. This is also one of the 
strengths of the paper as new data and information was revealed in this prostate cancer 
population; making it possible to use the EQ-5D data from this population and make 
comparisons of QoL assessments in other PCa populations using the same instrument. The 
paper was also the first where detailed PRO data was reported for enzalutamide with more 
details than just descriptive statistics. The positive effect over time was well illustrated with 
the analyses of the FACT-P total scores, clearly showing the positive effect over time with the 
new treatment, thus supporting a long term QoL effect of enzalutamide. 
The paper contributed not only to the overall understanding of the treatment benefit of 
enzalutamide, but also helped advance the understanding of Outcomes Research and its 
benefits within the company, and within the medical community for PCa treatments. 
 
The limitations of the study were in particular at the later assessment of week 61; the 
number of patients was low. For BPI, already at week 25 the number of patients was low. This 
weakens the results but may be mainly due to disease progression in the placebo group as 
patient discontinued reporting at that time.  
The paper presented the adjusted mean change in FACT-P scores over time. Another way, 
and one favoured by some regulatory agencies, has been to show results as Cumulative 
distribution functions (CDF). Handling of missing data can also be done with different 
methodologies. The next paper addresses this and presents results using CDF, as well as 
discussing missing data handling methods. 
 
4.3 Study Summary and Critique (Paper 4) 
Impact of enzalutamide on quality of life in men with metastatic castration-resistant 
prostate cancer after chemotherapy: additional analyses from the AFFIRM randomized 
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clinical trial. (Cella D, Ivanescu C, Holmstrom S, Bui C, Spalding J, Fizazi K). Annals of Oncology 
26: 179-185, 2015 
DOI: 10.1093/annonc/mdu510  
 
This paper reports results from the additional PRO analyses we performed from our AFFIRM 
clinical phase III trial, a randomized, double-blind, placebo-controlled study in prostate cancer 
treated with enzalutamide. The conceptual planning of this paper was similar to that of Paper 
3 and the clinical team had gained in understanding of the type of research my Outcomes 
Research team was conducting. Results were available from two of our key clinical phase 3 
studies and the knowledge and understanding of the PRO data was positively building up.  
At the same time, I needed to confirm and document how robust the PRO data was in terms 
of representing a true clinical benefit, rather than a false signal. This testing was done 
through different analyses on missing values. Key in my mind, was also always to construct a 
way to positively illustrate what the PRO data looked like over time, in comparison to placebo 
treatment. The research also advanced well in terms of providing a relatively rich data source 
of PRO data from all ongoing and planned future studies the company conducted. The paper 
therefore focuses on solidifying the strength of the positive signal we saw from both phase 3 
studies and ruling out bias due to missing data, while also exploring different ways to visually 
present our data. 
 
We had noted that regulatory guidance had called for increased collection of PRO data and 
for expressing the results using different methodologies, such as Cumulative Distribution 
Function (CDF) plots. This is a way to present the percentage of responders at each score 
change value and allows at a glance view of the difference between treatment groups. The 
CDF can visually express all possible score changes rather than a single score, as is the case 
for responder analyses. I therefore selected to report the CDF plots in this paper as a means 
of visualising the population benefit of enzalutamide treatment. 
 
PRO data was collected throughout the study using the FACT-P instrument. The FACT-P is a 
39-item questionnaire with five subscales for physical, - (PWB), social, - (SWB), emotional, - 
(EWB) and a functional-wellbeing (FWB), as well as a prostate cancer subscale (PCS). There 
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are also three indices with a Trial Outcome Index (TOI), a FACT Advanced Prostate Symptom 
Index (FAPSI) and a Pain-related score (PCS). 
Many scores, such as the FACT-P total score has derived a documented Minimally Important 
Difference (MID) range, which is empirically derived and documented. The MID is a way to 
express what such a summary score, or total score means when it comes to clinically 
meaningful change. In other words, when a score surpasses the established MID, one can 
claim that it has shown a clinically meaningful change that can be relevant for the patient.  
The longitudinal analyses on change from baseline on the FACT-P scores were analyses with 
the so-called Mixed effect Model for Repeat Measures (MMRM). The MMRM assumes that 
any missing data are missing at random. This is a reasonable assumption, but one cannot be 
sure that this assumption is valid and thus additional analyses using the Pattern Mixture 
Model (PMM) were carried out. These address the possibility that the missing data is not at 
random. 
 
The results from these analyses showed that overall 67.2% of the enzalutamide treated 
patients and 31.8% of placebo patients had no missing data at all. The treatment 
discontinuation was the reason for almost all patients dropping out, primarily due to disease 
progression. 
The MMRM analyses for all FACT-P scores were analysed and presented graphically as a 
mean change from baseline at the different time points of weeks 13, 17, 21 and 25. Using the 
pre-established MID to express the meaningfulness of these changes we show that all 
changes in the enzalutamide group were small or within the MID, in other words not clinically 
meaningful, whereas in the placebo treated patients all scores by week 13 or 17, except for 
the SWB and the EWB were clinically meaningful.  
The PMM analyses confirmed the results from the MMRM analyses, although the difference 
in change in the enzalutamide treated patients were smaller than in the placebo group after 
week 25 onwards. 
 
The CDF plots for each score were analysed and showed the same pattern in results with the 
MMRM/PMM analyses. The distribution functions were favourable to enzalutamide over 
placebo for the entire range of response levels. The MMRM and the CDF plot is represented 




Figure 4.1. Extracted from my paper showing change from baseline for placebo and 
enzalutamide using the MMRM and PMM analyses. The shaded area represents the MID 
range on the Prostate cancer subscale score. The solid lines show the MMRM and the dotted 
lines the PMM analyses. Green and pink are enzalutamide and blue and yellow are placebo 
responses (Cella et al., 2015: [Figure 1, p183] 
 
 
Figure 4.2. Extracted from my paper showing the CDF curve of percentage change of the 
Prostate cancer subscale score percent change from baseline at each visit. (Cella et al., 2015) 
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In summary, these analyses and figures show how more detailed analyses further support the 
improvement in HRQoL of patients treated with enzalutamide, specifically in improvements 
in pain and the increase in time for HRQoL deterioration observed with enzalutamide over 
placebo. The MMRM and the CDF graphical representation of the individual score change 
from baseline is increasing the understanding of the benefit for the patient and guide the 
patient as to what specific benefit he can expect, such as pain related benefit. 
 
The CDF plots show a clear separation of the curves in favour of enzalutamide and for all 
FACT-P scores and subscales, except the EWB, PWB and SWB. This helps to understand that 
the benefit is more marked for disease specific and symptom related measures rather than 
the general items such as Social or Emotional well-being. 
In terms of weakness or limitations with this paper, one can say that the chosen MMRM and 
PMM statistical methods are one of many that can be selected for analysing longitudinal data 
and handling missing data. There is however no universally accepted method by the scientific 
community and thus it is hard to conclude if this is the best method or not. Testing both for 
missing at random (MMRM), as well as not at random (PMM), and showing that there is no 
substantial difference in the results, strengthen the overall results of these analyses and 
confirming the impact of missing data is the same regardless of data missing at random or 
not. 
This paper provides additional methodological approaches, firstly to handle missing data 
(through the MMRM and PMM) and secondly on graphic representation of results. Handling 
of missing data is always going to be critical issue in PRO analyses, as this can lead to biased 
results, and a risk of not being a true representation of the results. The MMRM and PMM 
analyses are therefore important in support of the true positive treatment outcome of 
enzalutamide.  
 
Additionally, this paper made use of different graphical illustrations in presenting the results 
in a format that, at least some of the decision-making bodies and stakeholders are more 
familiar with. As such it is an important contribution to the evidence supporting decision-
making on if, and when, enzalutamide should be used in prostate cancer.  
One of the critiques of the paper is the complexity of the MMRM and PMM analyses. As they 
are not frequently used, the reader may find them difficult to grasp. The paper may have 
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benefited from further description of the methods to help the reader understand the 
methods and how this approach compares to other comparable methods on missing data. 
However, one still missing important piece of evidence, from a payer perspective, as well as 
from a patient and physician perspective, is how enzalutamide behaves in relation to other 
available treatments. To address this gap, the next research paper was designed to provide 
comparative, direct head-to-head data with one of the more frequently used prostate cancer 
treatments. 
 
4.4 Study Summary and Critique (Paper 5) 
Impact of Enzalutamide Compared with Bicalutamide on Quality of Life in Men with 
Metastatic Castration-resistant Prostate cancer: Additional Analyses from the TERRAIN 
Randomised Clinical Trial. (Heidenreich A, Chowdhury S, Klotz L, Siemens D, Villers A, 
Ivanescu C, Holmstrom S, Baron B, Wang F, Lin P, Shore N). European Urology, 2017, 534-542. 
 DOI: dx/doi.org/10.1016/j.eurouro.2016.07.027 
Decision-makers, HTABs, payers and treating physicians make daily decisions in terms of 
which drug to choose, based on efficacy, safety, possible cost benefits, and increasingly also 
based on impact on QoL for the patient. It was therefore crucial to have information available 
on how enzalutamide impacted QoL, as compared to other treatments. This research was in 
the planning stage already, after the first phase 3 data from PREVAIL was available. There was 
still an amount of uncertainty with regards to the effect size and how the drug stood up to 
comparators. A direct head-to-head study was therefore not a high priority for the clinical 
teams, and it required the team to get the timing right for such a study. However, through 
internal dialog and persistent focus, I managed to get the research off the ground. In 
addition, the team agreed that we include many PROs to enhance the clinical results with QoL 
information and build on the positive results from our previous studies.  
 
PROs included were the FACT-P, EQ-5D and the Brief Pain Inventory (BPI), short form. In 
addition, the outcomes related endpoint analyses were planned within a separate SAP to 
secure upfront detailed analysis. This paper reported on the results that corresponded to the 
outcomes focused SAP, which I conceptually planned in accordance with previous studies and 
with experience and insight gained from these. The analysis of QoL results focused on the 
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Enzalutamide study in comparison to the comparator of bicalutamide.  Bicalutamide is a so-
called second-line hormonal therapy with a well-established efficacy profile in prostate 
cancer. The lack of direct head-to-head comparative data with enzalutamide versus an active 
treatment, at the time of this research, was one of the key drivers for conducting this study. 
Several PRO instruments were included in this study to enable us to obtain, not only efficacy 
data, but also a direct comparison in terms of effect on HRQoL.  
 
The PRO data was collected throughout the study, with baseline measures, and an 
assessment every 12 weeks until discontinuation. The pre-defined MID, was obtained for all 
of the domain scores, the utility scores, and pain scores. The MID is generally expressed as a 
range. The lower number to interpret change from baseline between and within treatments 
was used. The upper limit was used for deterioration analyses.  Like in the previous paper, we 
analysed the data using the mixed effects mode for repeated measure (MMRM), assuming 
that missing data are at random. However, to address the possibility that the data is not 
missing at random, which could be due to toxicity, disease progression or death, also a 
second analysis using the Pattern Mixture Model (PMM) was performed.  
 
The results were reported from 375 patients randomised in the study. The median duration 
of treatment was for enzalutamide 11.7 months, and for bicalutamide 5.8 months. Although 
there was an over-time decline in all FACT-P domain scores, there was a significant difference 
in favour of enzalutamide at week 61 in three of the FACT-P domains (EWB, FAPSI-8 and the 
FACT-P) using the MMRM analyses. The PMM analyses showed seven of the domains to be 
significant in favour of enzalutamide (FWB, EWB, PC, FAPSI-8, TOI, FACT-G and FACT-P). 
However, no bicalutamide change from baseline showed a benefit over enzalutamide in any 
of the domains. 
 
The results from the EQ-5D VAS scores were maintained with both treatments in the MMRM 
analyses. For the utility score we showed that with enzalutamide, the score was maintained 
up to week 49, but with bicalutamide, the score deteriorated after week 13 with a clinically 
meaningful decline. For the pain analyses, with pain at its worst there was a smaller increase 




A strength of the study is that the results are consistent with those seen in placebo-controlled 
studies with enzalutamide (Beer et al., 2014, Loriot et al. , 2015) indicating that effect size 
and treatment benefits are not relative, but true outcomes. This study was also the first one 
to report on an active treatment comparison and including HRQoL data from the two active 
arms. Comparative studies with two active treatments in prostate cancer are rarely 
performed by companies. This paper therefore contributed to the common knowledge of 
how two active treatments compare, not only in terms of efficacy, but also in terms of impact 
on HRQoL for the patients. It also provided relevant data to HTABs on how the two drug 
classes may have a different mechanism of action and therefore cannot be seen as equivalent 
in the decision-making process. 
 
One can of course comment on the selection of comparator, as bicalutamide is used less and 
less given that drugs that are more effective are available. However, bicalutamide has long 
been a well-established treatment and thus provides a good reference for treating physicians 
in terms of both efficacy, but also in terms of safety and QoL benefits. The HRQoL were 
however only exploratory and had thus not been included in the analysis hierarchy as key 
primary or secondary end-points. This can be seen as a clear limitation as it weakens the 
significance of the outcome, at least statistically speaking. Future studies should consider 
including HRQoL as at least key secondary endpoints to strengthen the validity of the QoL 
messages. 
 
The next paper expands into other relevant safety concerns. The skeletal-related events 
(SRE’s) are one of the key concerns in terms of complications for the patient, and potentially 
an event that has major implications on the patient well-being and QoL.  
 
4.5 Study Summary and Critique (Paper 6) 
Skeletal-related events significantly impact health-related quality of life in metastatic 
castration-resistant prostate cancer: data from PREVAIL and AFFIRM trials. (Saad F, Ivanescu 
C, Phung D, Loriot Y, Abhyankar S, Beer T, Tombal B, Holmstrom S). Prostate Cancer and 
Prostatic Diseases (2017) 20, 110-116 
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DOI:10.1038/prostate cancern.2016.62  
The paper came about as a collaborative effort between the clinical team and my Outcomes 
Research team, as both the clinicians need to understand the impact of SREs, as one of the 
key safety concerns, as well as from an Outcomes Research point of view where SRE’s may 
have a dramatic effect both on HRQoL, as well as the HE modelling. As a result, I established 
the focus on the HRQoL work stream as a distinct and separate research question. This paper 
is the result of this research.  
 
While reporting on QoL aspects of prostate treatment it is important to understand what 
specific items of the HRQoL aspects has the biggest impact in terms of suffering, but also in 
terms of treatment costs and complexity of the disease progression, and/or with the 
treatment. The SREs as a safety event, is a summary term used for various skeletal related 
events. By definition, and for these analyses, the SREs include pathological bone fractures, 
spinal cord compression, palliative radiation or surgery to the bone as well as change in 
antineoplastic therapy secondary to bone pain. The SREs may cause decreased mobility, 
which can lead to loss of independency and thus a related decrease in HRQoL. All of these 
have been associated with increased mortality in patients with bone metastases (Howard, 
2016). This study examined the impact of the SREs on the HRQoL.  
 
The paper reports on the analyses of data collected in the two prostate cancer studies of 
AFFIRM and PREVAIL where the effect of enzalutamide was measured against placebo. The 
PRO instruments included in the studies were FACT-P as well as the EQ-5D. The pain was also 
assessed with the Brief Pain Instrument (BPI). The data was collected at baseline and weeks 5 
and 13 and every 12 weeks until discontinuation in the PREVAIL study. For AFFIRM there was 
data at baseline, week 13, 17, 21 and 25 and thereafter every 12 weeks until progression and 
discontinuation. To assess the change from baseline the Minimal clinically important 
difference, or the MID previously established was used.  
 
To establish what the impact of an SRE was on the HRQoL, all the assessments up-to-date of 
the SRE (any category), and the first post-SRE assessment were included. To evaluate the 
random effects for each patient trajectory of the HRQoL, a linear mixed-effect model to 
assess each patient’s effect before the first SRE was used. The predicted value of the post SRE 
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compared with the post-SRE value of the HRQoL was used to calculate the trajectory-adjusted 
mean change (TMAC). The clinical impact and meaningfulness of the TMAC results were 
interpreted using the previously mentioned MIDs.  
 
All results were analysed for all SRE data by, a) combined for treatment arms, as well as, b) 
stratified by treatment arm;  
a) Combined for treatment arms: 
The results from the PREVAIL study show that using the EQ-5D utility index decline, as 
calculated with the TAMAC change, the impact of any SRE category had a significant impact 
on the HRQoL, exceeding the lower limit of the MID range. The highest impact, as measured 
by the decrease of the utility index can be seen with spinal cord compression. Analysing the 
FACT-P domains, we can again see that spinal cord compression has the broadest impact with 
seven of the nine domains significantly diminishing.  
In the AFFIRM study 34% of the patients experiencing at least one SRE, with radiation to the 
bone as the biggest category (24% of patients with at least one SRE). The number of patients 
and the distribution of the SRE categories were similar in the two studies. Like in the PREVAIL 
study, a clinically meaningful and statistically significant decline in the FACT-P and FACT-G 
total scores with any SRE category was seen.  
b) Stratified by treatment arm: 
The data were analysed for both studies of PREVAIL and AFFIRM stratified by treatment. The 
results in PREVAIL showed a statistically and clinically meaningful decline in four FACT-P 
domains (functional well-being, prostate cancer subscale, FACT-P total score and FACT-TOI) in 
the enzalutamide treated arm after any SRE. In the placebo treated arm, there were no 
statistically significant declines in FACT-P outcomes, except for the physical well-being. For 
the AFFIRM study also showed a statistically significant and clinically meaningful decline in 
FACT-P total score, prostate cancer subscale and FACT-G total scores. Again, no significant 
change was seen with placebo.  
 
With this study, linking the quantitative PRO measures with the decline in the HRQoL and 
progression of the disease is done. An association between SREs and the impact of the 
patients functioning and decline in general of the HRQoL can been shown. As SREs have a 
significant impact on the patient’s functionality and HRQoL, and thus any effect one can have 
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delaying the onset of SREs will be a desired and good outcome for the patient and treating 
physician. 
 
One of the strengths with this paper is the fact that two of the enzalutamide studies were 
combined to look at a larger prostate cancer patient segment, which better reflects the 
population treating physicians have to deal with in every-day practice and thus provides a 
more holistic understanding of the effect of SREs. The studies also included several PRO 
instruments, which were here analysed in terms of association to SREs.  
 
As one PRO may provide sufficient sensitivity in terms of picking up meaningful differences in 
one domain, this may be the reverse with another instrument. Therefore, for instance, FACT-
P did not pick up on an association with pathological bone fractures with any significance, 
whereas the EQ-5D utility index did pick up such an association. The importance of having 
multiple PROs, including disease specific instruments, as well as generic health 
questionnaires, is underscored with these findings.  
 
The EQ-5D has often been described as a relatively blunt instrument, but these findings show 
that it can sometimes outperform other disease specific instruments, in terms of sensitivity to 
pick up meaningful changes. This may be an important strength and contribution of this 
paper. In the bigger picture of this research stream, the paper provided unique and important 
knowledge on how safety profiles can and will impact, not only on the clinical outcomes, but 
the relationship of this to the QoL of the patient. This QoL change will also then have an 
impact on the health economic model as both costs and decreased QoL will influence the 
cost-effectiveness of the compound. Perhaps equally important is that the paper articulates 
with more details and granularity on how the disease progression will impact on the patient. 
This is an important piece of information that can become a part of the dialog between the 
physician and the patient. Such information will enrich the dialog by providing patient 
relevant information in the hands of the physician in a format that speaks to the patient with 
information that he can relate to. 
 
As to limitations of this study, the methodology of using a trajectory-adjusted mean change 
(TMAC) for our calculations of the impact on HRQoL may not be the easiest to digest. The 
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audience for this paper may therefore be somewhat limited and we could consider adapting 
the results and output for a more clinical audience to reach better uptake within the medical 
community. Also, the decreasing number of patients in the placebo arm will make it difficult 
to analyse longer-term results. As noted, the analyses by treatment did not pick up the 
placebo decline in HRQoL, as expected, most likely due to the small numbers. This could 
therefore be a false conclusion. The data points available for analyses was drive by the study 
protocol. Therefore, any SREs may have had an earlier onset (time to first SRE) as the period 
between data collection was not able to determine the exact time of onset. It is therefore 
difficult to estimate the exact time of onset.  
 
4.6 Chapter Summary 
The chapter has provided multiple examples as to how PRO data should be analysed 
according to the instrument guidelines, expressing the results as summary scores or total 
scores, such as EQ-5D utility scores, FACT-P total scores and for instance FACT-P Prostate 
cancer subscale scores. The other important insight from this chapter is to explore different 
ways of expressing the results and correcting for statistical variability and missing data. This 
was done through the MMRM, the PMM analyses as well as expressing the results as mean 
change from baseline, but also cumulative distribution curves, all designed to enhance the 
way the reader can absorb the rather complex results from HRQoL analyses. The chapter also 
expanded the horizon into what is important from a patient perspective facing real life 
challenges, such as “what are my treatment options, what benefits and safety risks do they 
bring as compared to each other”. Comparative data is thus important, as is the impact on 
safety and disease progression issues, such as SRE’s. 
 
The wider implication and benefit of these papers is that they help paint a much richer 
picture of the patient benefits from the enzalutamide treatment in comparison to existing 
treatment of bicalutamide as well as help understand serious safety and disease progression 
concerns, such as SRE’s. For HTABs and other decision makers, these papers provide much 
needed additional granularity and data that help understand the clinical, economical and 
humanistic implications of this treatment, and as compared to other alternatives. This can 
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greatly facilitate for instance reimbursement decisions. These data also provide evidence that 
can support updating of treatment guidance and algorithms, as well as drug policy updates. 
 
In the next chapter, the importance of exploring the inherent richness of the PRO data within 
the different instruments will become evident. The connection to how PRO data and results 
relates to hard end-points and clinical outcomes is also important to establish.  
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Chapter 5: Exploring Alternative Methodologies for PRO Analyses 
5.1 Overview 
As seen in the previous Chapter 4 and in papers 3, 4 and 5, reporting out on the prostate 
cancer PRO results and the summary-scores can provide insight into how the patient feel and 
change over time, and provide insight into how he may benefit from treatment options as 
compared to placebo or alternative active treatment. Likewise, in paper 6 it is shown that 
linking key adverse outcomes (SREs) with the effect on HRQoL results is possible and this 
helps with interpretation of the PRO results as well as can be used to estimate for instance 
cost-savings. With the summary scores however, it still can be difficult to fully understand the 
details behind why total scores report out in a certain way, and specifically what drives such 
change, what domain or symptom makes the patients feel the HRQoL go up, or down.  
 
The research we had conducted so far, and reported on in previous papers, reflected a point 
in time where we could clearly see a general positive impact from enzalutamide; substantially 
benefiting the patient through increased QoL, or at least diminishing the deterioration of the 
QoL. However, even with multiple instruments, which in themselves enabled us to pick up 
different aspects of the disease progression, we were lacking an in-depth insight as to what 
exactly is behind the HRQoL benefits. What were the precise benefits that the patients 
experienced that was driving the overall QoL scores to remain positive? The following 
research question was therefore formulated through this knowledge and our research now 
focused on a more deep-dive into the PRO domains and on conducting further item-specific 
analyses. 
 
5.2 Study Summary and Critique (Paper 7) 
Health-related quality of life effects of enzalutamide in patients with metastatic castration-
resistant prostate cancer: and in-depth post hoc analysis of EQ-5D data from the PREVAIL 
trial. (Devlin N, Herdman M, Pavesi M, Phung D, Naidoo S, Beer T, Tombal B, Loriot Y, Ivanescu 




This paper reports out the results of in-depth analyses of one of the PRO instruments, the EQ-
5D from the PREVAIL study. Additional in-depth analyses are performed, while trying to pick 
up where the changes are happening, in other words, what domains and symptoms are 
impacted. The EQ-5D is a generic PRO instrument, as opposed to the disease specific FACT-P 
for instance. The way the EQ-5D is constructed is that it is composed of five different 
domains; the Mobility-, Self-care-, Usual Activities-, Pain/Discomfort-, and 
Anxiety/Depression-domain. Each of the domains will be asking for a three-level input, with 1 
as no problem, 2 meaning some problems, and 3 meaning extreme problems. These domains 
are combined to give a unique so-called health state for each patient. A patient in full health 
would score a five-digit code of 11111, indicating no problem in any domain. These health 
states can be converted to a summary score, or EQ-5D index. This is done by applying weights 
derived from a general population in different countries and gives you the so-called utility 
index, which is a number from 0-1, where 0 equal a state as bad as death, and 1 equal a state 
in full health. The instrument also collects the EQ-5D VAS score, which is a straightforward 
Visual Analog Scale of 0-100, with 0 meaning worse imaginable health state and 100 meaning 
the best imaginable health state. Few studies with prostate cancer patients have included the 
EQ-5D instrument and none has previously reported out EQ-5D results in this disease 
segment of chemo-naïve prostate cancer patients. The EQ-5D data was obtained at baseline, 
week 13, and every 12-week until discontinuation or disease progression. Data only until 
week 61 were analysed due to reduced sample size after this. 
 
The change on individual dimensions, time-to-event analyses, as well as the Paretian 
classification of Health Change (PCHC) were analysed. All of the EQ-5D dimensions were 
summarized for the proportion of patients reporting either no change, some change, or 
extreme problems. The PCHC analyses look at the EQ-5D health state and is classified as 
either “better”, “worse”, or as “mixed”.  The proportion of patients with an index score of full 
health (a score of 1) was also analysed. The time-to-event analyses were used to estimate the 
benefit of enzalutamide versus placebo with the effect of delaying or preventing 
deterioration of the patient’s health. Patients who had full health, in other words a health 
state of 11111 at baseline was used to assess time to worsening. 
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The results from the individual dimension analyses show a significant effect of enzalutamide 
in the between-group difference for the Pain/Discomfort dimension to week 37, as well as for 
the Anxiety/Depression dimensions at week 13 and for Usual Activities dimension at week 25. 
For the patients with full health (index value of 1), there was a clear tendency for 
enzalutamide to show greater proportion of patients remaining in health stake 11111 up to 
week 37, although statistical significance was only seen at week 13 (see Figure 5.1 below). 
In the PCHC analyses, we showed that a greater proportion of patients reported 
improvements on enzalutamide than on those on placebo. The between group differences 
were statistically significant at weeks 13, 25 and 49 (see Table 5.1 below) 
The time-to-event analyses showed a statistically superior result with enzalutamide over 
placebo in most dimensions. This included divergence from full health, time to decrease of 
the EQ-5D index or VAS, time to deterioration of Self-care, Pain/Discomfort and 
Anxiety/Depression. 
 
Figure 5.1 from my paper (Devlin et al., 2017), page 6. Proportion of patients in full health, 
reporting an EQ-5D state of 11111 (full health) as expressed over time during different visits 
 
Table 5.1 show the Pareto classification of health change classification of changes from 
baseline in EQ-5D dimensions 
 Enzalutamide (n=872),  Placebo (n=845),  P value 
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n (%) n (%) 
Week 13 n=783 (89.8%) n=605 (71.6%)  
Worsening 208 (26.6%) 230 (38.0%) <0.0001 
No Change 337 (43.0%) 242 (40.0%)  
Improvement 190 (24.3%) 94 (15.5%) <0.0001 
Mixed change 48 (6.1%) 39 (6.5%)  
Extracted from my paper (Devlin et al., 2017), page 6, and shows the week 13 results 
 
The paper is able to expand the understanding of the previously reported PREVAIL results 
showing a significant prolongation of enzalutamide time to deterioration of the EQ-5D index 
and VAS score, while helping to understand what was driving the changes. For instance, while 
using the PCHC approach, one can show a considerable movement between levels of pain 
and discomfort in level of patients improving, respectively worsening. In conclusion, there is a 
significant HRQoL benefit from enzalutamide and that this is largely driven by changes in 
Pain/Discomfort and Anxiety/Depression. 
 
These findings are completely new and revealing in terms of providing further in-depth 
understanding of the effect of enzalutamide and the impact it has on patients. The findings 
also confirmed our thinking that there are some domains and items and outcomes that are 
more affected by the benefit of enzalutamide than other ones. Furthermore, the insight 
obtained from these EQ-5D analyses, provides new ways of analysing and using the data 
obtained with the EQ-5D instrument. From an academic point of view it helps move the 
understanding of the EQ-5D, as a generic instrument, well beyond the much-reported utility 
index, or the VAS score. This paper is also the first paper reporting in-depth results from a 
generic PRO instrument in this prostate cancer segment. The paper thus highlights, again, the 
need for both generic as well disease specific PROs to be included in clinical studies, as 
previously unknown information can be found and disseminated through these analyses. The 
analyses of the EQ-5D dimensions helped understand previously reported summary scores 
(Loriot et al., 2015) by exploring and pointing to specific symptoms and disease items that 
may be driving the changes in the summary scores. 
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This paper tremendously advanced our understanding of the specific symptoms that most 
likely were manifesting themselves in the improvements of the total PRO scores after 
enzalutamide treatment. Subsequently we proceeded with item-specific analysis of all other 
PRO instruments to complement these findings. However, this research was ground-breaking 
for us in terms of finally being able to articulate specific impacts on symptoms on the benefit 
of enzalutamide, something that we had not been able to do before. It is a lot more 
meaningful to speak to a patient, or a physician about impact on the specific items of self-
care, or on pain, than to say that an overall benefit on QoL is a documented with 
enzalutamide treatment. 
The PRO instruments are originally constructed through careful consideration and inclusion of 
symptom items and domains that are relevant for the patient. Therefore, a lot of relevant 
disease information on how the patient feel and function is captured. Reporting out the 
results from these through complex algorithms can however hide some of the information 
and cloud the understanding of the results. The paper thus highlights the need to fully 
explore all of the intrinsic data captured by the instrument. In addition, from an ethical point 
of view, colleting PRO data from patients is undoubtedly some burden for the patient. Thus, 
to not fully explore and understand the PRO data collected is a waste of time and resources 
and can be a missed opportunity to understand the benefits the patients have reported on in 
the PROs. 
 
As to the limitations of the study, the relatively unknown methodologies used, like the Pareto 
classification, not frequently seen with PRO analyses; thus it may be difficult to understand 
for some readers. The acceptance and understanding of the methodology will benefit from 
further studies being published using these methods. Furthermore, the numbers of patients 
over time was declining due to disease progression. This will make the robustness of the 
results at the later visits less strong. Another weakness is also the lack of data after disease 
progression. Ideally, one would need to fully show both high number of patients throughout 
the treatment visits, as well as link the results to the outcomes once new treatments are 
initiated. This would provide a full picture of the HRQoL progression.  
 
The next and last paper expands the understanding of the PRO and HRQoL data, and the 
relationship to clinical endpoints. If we can show that there is a link and association between 
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how the PROs behave in translating the patient’s disease progression with clinical hard-
endpoints, then there will be a prognostic value within the PROs and maybe in the future we 
will be able to replace clinical assessments and tests with PROs. 
5.3 Study Summary and Critique (Paper 8) 
The association between health-related quality-of-life scores and clinical outcomes in 
metastatic castration-resistant prostate cancer patients: Exploratory analyses of AFFIRM 
and PREVAIL studies. (Beer T, Miller K, Tombal B, Cella D, Phung D, Holmstrom S, Ivanescu C, 
Skaltsa K, Naidoo S). European Journal of Cancer 87 (2017) 
DOI:10.1016/j.ejca.2017.09.035 
 
At this stage research on enzalutamide had moved ahead quite substantially from when we 
had started this research, in terms of understanding our compound; and how to plan, 
implement, conduct and report on our Outcomes Research. I had by now, a good 
understanding of the impact of enzalutamide on the QoL and, indeed even how the benefit of 
the drug manifested itself, through which domains. As a final part of this research journey, 
one of the challenges was related to communication; and how to best make PRO results and 
Outcomes Research more meaningful to our primary stakeholders such as the treating 
physicians and the patient. The research question was therefore to see if I could link clinical 
endpoints with PRO results and QoL data. Could I correlate the Outcomes measures in any 
meaningful way with clinical outcomes and was there a clear correlation with positive PRO 
outcomes with clinical endpoint improvements? 
The previous papers, numbers 3-7 were exploring different approaches and how data can be 
analysed, and how the data can be presented in different ways to make it more meaningful to 
stakeholders. This paper takes one additional step linking the PRO outcomes and results with 
clinical endpoints, given that the changes in HRQoL is an important determinant of the value 
of cancer treatments. 
 
Traditional clinical endpoints of Overall survival (OS) and radiographic progression-free 
survival (rPFS) are well understood and valued by clinicians. The Prostate Cancer Working 
Group (PCCTWG3) has recommended evaluating any change in individual outcomes, such as 
the PRO measures, with longer-term outcomes, such as the OS or rPFS (Scher et al., 2016). 
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Indeed, there has been reports where the association between an improvement in HRQoL 
and the improvement in clinical outcomes has been shown (Gupta, 2013, Sullivan et al., 
2007). However, the relationship between the clinical outcome measure, such as OS and rPFS 
and that of the outcome of HRQoL is limited. This makes it difficult for clinicians to relate to 
PRO results, or fully comprehend the implications of PRO data. 
 
This paper used data from the PREVAIL and AFFIRM trials, where patients were treated with 
enzalutamide for prostate cancer. For these analyses, the FACT-P instrument results were 
used. All of the FACT-P summary scores and domain scores were analysed. The analyses were 
done to investigate the relationship between the OS and rPFS and all of the HRQoL measures. 
In total, all FACT-P data and all domains were used for the analyses. The analyses were done 
using Cox proportional hazard models with baseline or time-dependent covariates fitted to 
time-to-event data on OS and rPFS separately. The hazard ratio (HR) with associated 
confidence intervals (CI) of 95% for the HRQoL variables were used as the key measure. This 
was calculated as the hazard of rPFS or OS per minimally important difference (MID) score 
change in the HRQoL variable. 
 
The results from the univariate analyses from both studies AFFIRM and PREVAIL showed a 
clear association between baseline HRQoL and the clinical endpoints of survival (OS) and 
rPFS. The multivariate analyses from AFFIRM baseline HRQoL for rPFS was associated with the 
FACT-P total, FACT-G total, the TOI and the EWB as prognostic factor of rPFS with a (HR; 0.92-
0.95). In addition, for OS, the HRQoL values were of prognostic value, with higher values 
reducing risk of death by 6-17%. Similar association of HRQoL changes over time and OS were 
shown, with all FACT-P domains associated with OS (HR; 0.75-1.15). In addition, for rPFS the 
results show FACT-P domains (except FWB, EWB and PCS) to be prognostic of rPFS (HR; 0.86-
1.07). 
 
For the PREVAIL study, somewhat similar results can be seen. In general, the point estimates 
for HRs are smaller in the time-dependent model as compared to the model with the baseline 
values only. Figure 5.2 extracted from the paper shows the association between longitudinal 
HRQoL and rPFS (A) and OS(B) in a multivariate model from the PREVAIL data. This is 




Figure 5.2. Extract from this paper showing the results of longitudinal multivariate analyses of 
the PREVAIL study on the association between HRQoL and rPFS and OS. (Beer et al., 2017) 
 
This study analysed the data from two enzalutamide studies and explored the association of 
survival (OS) outcomes with both baseline and longitudinal HRQoL scores. The results indicate 
that there is indeed a correlation between the HRQoL, both for baseline values as well as for 
the over-time values for both rPFS and OS in the patients with prostate cancer. The PRO data 
can therefore be informative in decision-making and influence the physician’s treatment 
approaches as well as help better understand the progression of the disease. 
 
As there are relatively few papers showing the link between PRO results and clinical 
outcomes, this paper helps advance the science on this front. The relationship with baseline 
values of PROs in PCa has been reported, but few studies can be found where the longitudinal 
prognostic value of HRQoL in PCa is explored (Traina et al., 2015). My paper therefore 
contributed to the understanding not only of enzalutamide in this context, but also to the use 
of PROs as a predictive outcome of in PCa in general. Combining two enzalutamide studies 
provided a larger population, providing a good number of data points of both PRO and clinical 
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data. Both baseline and time-dependent variables were used which expands from other 
similar papers, where focus was on baseline or pre-treatment data. 
 
There is a clear need for physicians to better understand how to read, understand and relate 
to PRO results in their day-to-day clinical practice. These two papers (paper #7 and #8) help, 
first by extracting explicit information about the patient functioning on a symptom-item level. 
Secondly, by providing the link of the PRO results with clinical assessments and outcomes. 
This will greatly enhance the way physicians can relate to what the PRO data tells them. 
Collecting PRO data from the patients is a relatively low-cost and low-burden exercise, as 
compared to expensive clinical tests and analyses such as scans and laboratory testing. If PRO 
data is able to capture disease progression as rapidly as an expensive clinical test, then 
implementing PRO data collection in routine clinical practice can be highly cost-effective and 
effective way to manage the patient care, and at a much lower cost. 
 
One of the limitations of this study is the post-hoc nature of the analyses, which of course is 
the nature of such exploratory work. In addition, in terms of the predictive model, other 
more sophisticated models could be considered, but for investigating the association 
between the HRQoL domains and survival and disease progressing, this is deemed sufficient. 
There is however the probability that this is a false conclusion. Further studies are also 
recommended to validate the findings and associations we found. 
 
5.4 Chapter summary 
The chapter is a summary of perhaps the most important papers that I published. Firstly, it 
provides an example, based on all previous research we had conducted, for how by 
undertaking further analysis, focusing on specific items within the PRO instruments, we were 
able to extract much more and more relevant information about the treatment benefit. 
Subsequently I conducted item-analyses on all of our PRO instruments to gain a much richer 
picture of the patient benefit, one which we can articulate through publications and other 
educational material. Through this research I managed to open up a whole new dimension of 
meaningful information on patient relevant outcomes that was not there before. The EQ-5D 
instrument here serve as one example of how the construct of the PRO instruments can be 
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rather complex and results presented in total scores that are difficult to interpret. When the 
individual items are in the focus, trend and longitudinal analyses can provide enormous 
insight. This helps stakeholders find the underlying cause of the issues, from the perspective 
of the patient, and thus can make more informed decisions on what treatments offer and 
differentiate between treatments. 
 
Furthermore, with my research, I managed to make the important link between clinical 
outcomes of PFS and OS over time, something that has not been widely reported before. 
Some papers have indeed made the correlation of PROs as predictive of baseline values for 
PFS and OS, but not beyond that. The contribution of these findings is therefore quite 
significant. The ultimate goal may be to get PROs to become part of the every-day decision 
making for physicians; potentially replacing some clinical assessments, which are often more 
expensive and much more time consuming. If the PRO trend can indeed predict disease 
progression, or OS outcomes, this can be used as a simple mean to modify ongoing 
treatments or predict complications, eventually saving time, resources and money for health 
care providers. This paper therefore was a culmination of the research I conducted, as the 
impacts of our results has the potential to change clinical practice. 
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Chapter 6: Summary, Recommendations and Conclusion 
 
6.1 Summary 
The aim of the thesis was to demonstrate and discuss how the use of PRO data in 
pharmaceutical drug development can enhance the understanding of prostate cancer during 
the disease progression. The PRO data can reduce uncertainty in decision-making and 
improve patient care. Such data will help to enhance our understanding of our drugs, thus 
enable companies to prepare better for reimbursement and market access negotiations as 
patient specific benefits can be better articulated. The evidence must be generated during 
the drug development process and be available for HTAB submission. The thesis also 
discussed how industry currently conduct prospective and retrospective PRO analyses and 
provide examples of how these can be focused to a more targeted, fit-for-purpose research, 
eventually better meeting the needs of stakeholders. The pharmaceutical industry should 
become more familiar with the concept of patient-centricity and take patient-centeredness 
to heart within the organization in order to meet these demands.  
The field of PRO, HRQoL and Patient-centric research is rapidly evolving. Recent changes in 
the mind-set of regulatory agencies has opened up more opportunities to include PRO 
related information into regulatory submissions and perhaps provides opportunities for 
HRQoL information to be used more extensively in decision making. This can be seen for 
instance in the EMA Strategic reflection outline for 2025, where one of the five strategic goals 
for regulatory science is to ensure patient-centred access to medicines is advanced (EMA, 
2019). Specifically, EMA brings forth the use of PROs and the need to further update 
guidelines on use of PROs in terms of study design and analyses of the date (EMA, 2019). 
Likewise, HTABs are expanding the expectations for new drugs and expect QoL related 
information. New treatments must not only provide an improvement of the efficacy and 
safety of drug treatments, but also providing patient relevant improvements in QoL, while 
still being cost-effective. The industry has sometimes paid a high price, as drugs have had to 
be withdrawn from the market due to lack of appropriate evidence to support their products. 
Such was the case for instance with Exubera® where the need of the patients and payers had 
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not been appropriately catered for, even with a more than USD 2 billion research investment, 
the drug failed to meet the expectations of the stakeholders and eventually withdrawn 
(Oraiopoulos and Dunlop, 2017).  
 
The PRO and HRQoL focus of the eight papers have contributed to the understanding and 
help explain the benefit of enzalutamide in the treatment of PCa. The papers provide, new 
and ground-breaking information or evidence, in addition to the clinical papers, which report 
more traditionally on the primary endpoints. As PCa gets more treatments options, it is 
important to understand and distinguish between the treatments. The QoL aspects are an 
important part of this understanding. 
6.2 Contribution of Research to Knowledge and Implications of the Thesis  
Specific key contributions from the research that I, and my research team, conducted have 
included expanded learning on how enzalutamide impacts patients’ lives. The iterative 
learning from the conduct of one research paper after the other, collectively created a whole 
new framework for how Outcomes Research can more effectively be implemented within 
drug development. My personal learning has been steep, at least on a conceptual level, 
where I have gained insight and understanding on how to position and execute research in 
front of critical internal reviews; and additionally in terms of the trial and error on how PRO 
research can best be planned, implemented and how to best construct the analyses plans 
(SAPs). In general, and perhaps most importantly, I have learnt how Outcomes Research can 
be introduced as a fairly unknown topic into the public domain while publishing papers on 
our results. Thus, the collection of these publications, coupled with my personal research 
journey of learning has enabled me to use the papers as the building blocks for the 
framework that I present here at the end of this chapter (see Table 6.1) 
Prostate cancer as a disease provides a formidable challenge to society and health-care 
providers in terms of humanistic suffering, burden of disease for the patient, burden for the 
caregivers and contributes to the increasing health-care costs. At the same time, new 
treatments are made available at a rapid pace and the drug development focus of these new 
treatment modalities must secure adequate evidence to support the best use of these 
treatments and help direct and secure funding to the best available options. While the thesis 
 73 
makes use and reports on well-received papers by the medical community, as evidenced by 
comments from the journal editors, on how PROs and HRQoL can be presented, these same 
papers may not always be adequate, or the most appropriate to address a different 
stakeholder community, such as HTABs, payers and patients (Fallowfield et al., 2016; Porter 
et al., 2016).  
Methodologically PRO developers are bound by strict criteria to ensure the PRO instruments 
measure meaningful signs and symptoms, while also ensuring they are able to pick up change 
and do it consistently throughout populations. Standardized methods are also required to 
report the results from these instruments so that results can be compared between studies 
(Patrick et al., 2011a, b). While this is scientifically the only accepted approach in the conduct 
of such research so far, one also need to provide insight to the burden of the disease, and to 
the impact, drug treatments have on the patients in a meaningful and understandable 
format. With the initiatives of EMA and the FDA, as well as some of the HTABs, the direction 
of the PRO research is now focusing on not only domain analyses, but also item analyses and 
psychometric and exploratory analyses to fully be able to understand what is truly driving the 
change in the patient’s reported quality of life (EMA, 2016; FDA, 2017). 
The thesis advances the understanding of how Enzalutamide works and enhances the QoL of 
prostate cancer. With Paper 1 and 2 the foundation of understanding prostate cancer and the 
impact of the disease was set, at least in one of the patient segments of PCa (van Nooten et 
al., 2012; Tomaszewski et al., 2017).  Building on this, Papers 3, 4, 5 and 7 provided new and 
sometimes unique data of how we can measure the patient progression, using PRO data to 
illustrate this (Loriot et al., 2015; Cella et al., 2015; Heidenreich et al., 2017). Such was for 
instance the reporting of the EQ-5D data that had not been reported before in the PCa 
segment (Devlin et al., 2017). Collectively these papers have helped tremendously to 
articulate the effect of and advance the understanding of the benefit of Enzalutamide on PCa 
patients.  
6.2.1 A Framework for integration of PRO research within drug development 
Extrapolating from these approaches, methodologies and reporting practices, one of the key 
contributions of the thesis is that it creates a framework for how to integrate PRO research 
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into pharmaceutical drug development. It provides examples for how to analyse and report 
the results from PRO research and how to explore the intrinsic value of the PRO data through 
item analyses of the instrument. Another key contribution is also in providing evidence of the 
linking of PRO outcomes to clinical endpoints, such as Survival benefit (OS) (Beer et al., 2017) 
As a consequence, the PRO results must be reported and presented using methodologies and 
output as required by the individual instruments, but data should also be explored beyond 
these and with different methodologies. The papers in this thesis reports on both of these 
methods. It includes also the conduct of longitudinal change from baseline analyses, conduct 
of sensitivity analyses and estimating the impact of missing data, for instance with MMRM 
and PMM analyses and expressing results with CDF plots as in Paper 4 (Cella et al., 2015). 
Understanding what the most relevant safety concerns are is also important, both from an 
impact point of view, but also from a cost-consequence point of view, as reported in the 
Paper 6 on enzalutamide and SRE’s (Saad et al., 2017). Equally important is that we 
encourage the industry to conduct further in-depth analyses and break out of the pre-set 
mould of how data is analysed and used. This was done in the Paper 7 on how data can be 
analysed differently, in this case with the EQ-5D instrument (Devlin et al., 2017). This will 
provide evidence that allows the physician and the patient to have a meaningful dialog on 
how the drug affects the disease symptoms, what options are the best for the individual 
patient, and what improvements can be expected over other treatments (Heidenreich et al., 
2017, Beer et al., 2017). 
The research which has been presented in this thesis and the collective learning from this has 
enabled me to synthesise this into a meaningful output, in terms of how clinical research 
perhaps should be conducted, I have created a type of best-practice framework for this type 
of research. The framework is thus a collection of both the iterative learning, which was 
possible thanks to the continued research with the same compound for several years, 
alongside the intellectual learning related to having conducted this research. This has enabled 
learning about the biggest hurdles and pushbacks within the pharma companies. Each of the 
papers contribute individually to the framework by providing examples of how that step of 
the research can be conducted, while also serving the purpose of informing stakeholders. 
 
 75 
Table 6.1 A Framework for integration of Outcomes Research within drug development 
 Task Paper contribution 
1 Preparation of prospective PRO strategy 1 
2 Engagement with authorities (regulators and HTABs) for early 
scientific dialog and alignment on data needs and relevance of 
these in the minds of authorities 
1 
3 Conduct of Patient qualitative and quantitative research. 
Ensure adequate perspective of patient is documented for 
signs, symptoms and impacts of disease and treatments 
1 
2 
4 Securing the integration of Outcomes Research relevant 
endpoints into clinical trial program from early phase onwards 
1, 2, 3 
 
5 Conduct of PRO analyses  
5a Following validated scoring manuals and guidance for 
individual instruments 
3, 4, 5, 6 
5b Conduct of exploratory analyses, such as item analyses on 
[patient] relevant domains 
2, 7 
5c Conduct analyses on correlation between PRO outcomes and 
clinically relevant endpoints and outcomes 
8 
6 Articulate results from PRO data in simple, meaningful ways to 
enable value messages relevant for regulators, payers, HTABs, 
physicians and patients 
2, 3, 4. 5, 6, 7, 8 
I believe this framework provides a relevant, patient-centred approach that adequately 
reports out the evidence to all stakeholders. Decision makers can get clear, easy-to-
understand data that will reduce uncertainty in their decision-making. Health outcomes can 
therefore be optimized, and treatments directed towards the options that best fit the 
patients need, reduce cost and unwanted suffering. PRO data should be used in daily practice 
to help guide physicians in patient care. If sufficiently strong evidence is obtained in linking 
the PRO outcomes with well-established hard clinical endpoints, such as OS, then they can 
become a highly cost-effective replacement of clinical measures. Ultimately such practice can 
become an integrate part of health policies and best practice guidance for how to treat PCa, 
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ultimately saving cost and help advance medical practice. The introduction of such updated 
treatment guidance may advance the use of patient relevant QoL data and help facilitate and 
enhance the dialog between the patient and the physician. 
6.3 Limitations of the Thesis 
There are some limitations of the current thesis. As stated in the introduction, due to the 
nature of the research within drug development, and where my colleagues and clinical team 
were when the research started, the only true focus of my Outcomes Research has been 
through the means of PROs and integration of PROs. Patient centricity is much more than 
PROs alone, and much more work could be done in understanding the patient experience 
while they are going through the journey of their disease progression. 
Another limitation is the lack of prospective overall analysis plan for how to conduct the 
Outcomes Research and statistical analyses for the PRO data. A prospective, over-arching 
analysis plan would help to establish the value of such Outcomes Research in the minds of 
the clinical team and internal stakeholders, and by doing this, the acceptance of the 
Outcomes strategy would be established, and could become part of the a priori testing 
hypotheses of the clinical research program. Due to various constraints and concerns, most of 
the PRO analyses conducted were either exploratory in the statistical hypothesis plan or done 
as post-hoc analyses. This may reflect a lack in confidence in how well the PRO instruments 
may pick up meaningful change, or for fear of lack of statistical power to allow PRO analyses 
to take a key primary or secondary position. As many new papers are now reporting out on 
the enzalutamide PRO results, confidence in how this type of evidence can be used to inform 
external stakeholders is building up and further acceptance of the PRO is as part of the 
statistical hierarchy is growing.  
Another limitation is the definition of MID’s for each and one of the PROs reported. As MID’s 
are one of the more widely accepted methodologies for expressing what change from 
baseline is reaching a level of improvement, or deterioration, and that can be classified as 
clinically meaningful, the definition of what those MID limits are is of high relevance. For the 
publications used in the thesis, available, published MID’s were used. However, the validation 
methods for how the MID’s were established are not always well documented, and for some 
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of the PRO is used, there is no pre-defined MID’s, like for instance for the PR-25 
questionnaire. For some HTABs, this is a very important point and they have published 
guidance on how MID’s are used to establish clinical relevance of the PRO results. Thus, only 
by providing solid evidence on how the MID’s are derived and how improvements can be 
observed, as a change over the MID threshold, will the data be considered by some HTABs. 
This area of research is not covered, and this could expose the data to critique in terms of 
clinical meaningfulness of the results. 
Finally, the present research overall is focussed on providing PRO related evidence and value 
of enzalutamide, as reported out, one study after the other. This is a natural evolution of how 
pharmaceutical drug development is done and how clinical studies are reported out. 
However, in ideally the PRO and HRQoL analyses should follow a strategic, a priori, plan that 
prospectively inform the study design of appropriate integration of PRO instruments, both in 
terms of data collection time points as well as securing prostate cancer appropriate PRO 
instruments are used consistently in studies to allow comparative data across studies in the 
disease spectrum. This requires talking to the patients and conducting desk research early in 
the drug development process, in order to fully understand the key issues, the patient is 
facing with the disease. This is one of the short-comings and the reason for why I duly call out 
for this in my proposed Framework (Table 6.1). 
6.4 Recommendations for Future Studies and Research 
The field of PRO and QoL related research is evolving rapidly. This rapid evolution provides for 
many opportunities, both in terms of further standardization of methodologies, for instance 
in the field of handling missing data. It also provides for technological solutions for patient 
level data capturing that were not available a few years ago. One such field of technological 
advancement is the use of Multidimensional Computer Adaptive Testing (MCAT) to provide 
an iterative item level data capturing of the most relevant items (Morris et al., 2017). The 
MCAT builds on item response theory and computer adaptive testing. This methodology 
should at least be explored in future studies. 
The item analysis should also be advanced in the enzalutamide, and other PCa studies, to 
provide further support to the existing conclusions and evidence. Indeed, further studies are 
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progressing (ARCHES; ClinicalTrials.gov.NCT02677896). Given the positive results of the 
previous papers, the study team has agreed to include the PRO analyses in the primary 
hypothesis testing hierarchy for this study and my team is preparing for such analyses. These 
analyses will provide both domain, - as well as item, -analyses. Future regulatory submissions 
of enzalutamide will be in a position to  provide sufficient evidence to support additional 
label claims based on PRO and HRQoL data, and thus enable HTA submissions to solidify and 
enhance the patient experience sections. There are thus future opportunities for research in 
the field of PCa. Studies should secure PROs are included and that prospective plans are in 
place for analyses, both with the pre-specified algorithms, as well as item analyses.  
Publishing further data and results need to cater for different audiences and different 
stakeholders. The HTABs need to understand how to interpret QoL data and how to translate 
this into benefits from a payer perspective. The treating physician is interested in using QoL 
as an additional measure of treatment effectiveness and benefits. The patients need to 
understand how the treatment may affect or improve his QoL. Publication plans must 
consider these different needs and publish in both clinical and other types of journals. 
More concretely and as a next step and for the advancement of this research, I will aim to 
publish the framework as a follow-up publication to my first paper (Paper #1). I believe this 
framework may serve the industry well, if focusing on the educational aspects as to how to 
integrate PRO research and adapt to new requirements from the regulators (FDA, 2017, EMA, 
2017). The industry is continuing to struggle internally with the need to secure support, 
funding and resources for conducting Outcomes Research and also phase challenges with 
reporting outcomes results in such a way that the evidence has impact and is useful for the 
patients.  
Given the importance of my findings for enzalutamide, but also in terms of our internal 
structural shortcomings, I also believe that this research, and the learnings summarised in this 
thesis can serve me within my own organization and can be used for internal training of 
stakeholders.    
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6.5 Conclusion 
In conclusion, the thesis has provided the support of the primary objective of the thesis. The 
PRO research provides structure for how PRO research should be implemented in drug 
development (Paper 1), as well as examples for how PRO analyses can provide over and 
above information as compared to standard PRO analyses, relevant for the patient (Paper 4, 
5, 6 & 7). Lastly, it provides evidence linking PRO results with clinical outcomes and 
endpoints, such as OS (Paper 8). This can ultimately spare patients from unnecessary testing 
as PRO data can be used as predictive measures of outcome. All this provides additional 
information relevant to stakeholders and thus enhances the understanding of prostate cancer 
and how the outcome of patient care is improving with enzalutamide treatment. This is 
decreasing the uncertainty in decision making and thereby increasing the efficiency of health 
care in general.  
As a conclusion of my work and the thesis: 
The use of PROs in drug development enhances the understanding of prostate cancer 
progression as well as treatment impacts. PROs provide patient relevant information, 
reducing uncertainty in decision-making and thus help improve patient’s care, while 
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